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Abstract 
Damage to the central nervous system (CNS) results in permanent 
impairments. These are at least partly due to astrogliosis and subsequent glial scars 
formation, which block the regeneration and remyelination of neuronal cells. 
Associated with the above, the levels of pro-inflammatory cytokines, particularly 
tumor necrosis factor-alpha (TNF-a), were remarkably increased after brain injury, 
suggesting TNF-a induced astrogliosis. Recently, it has been reported that blocking 
the beta-adrenergic receptors (p-ARs) with antagonists reduced astrogliosis. It seems 
that TNF-a and p-AR are closely related in the formation of glial scars. 
The aims of this project are to investigate the role played by TNF-a and 
(3-adrenergic mechanism in astrocyte proliferation, an event closely related to 
astrogliosis. Besides, attempts were made to examine the interrelationship between 
TNF-a and P-AR in astrocytes. The methods used were reverse 
transcription-polymer柏e chain reaction (RT-PCR) and western blot analysis. 
In the present study, it was found that astrocyte proliferation was stimulated by 
TNF-a. Interestingly, it was observed that specific antibody against TNF 
receptor-type 2 (TNF-R2) acted as a receptor agonist to stimulate astrocyte 
proliferation, suggesting that activating the TNF-R2 could induce the proliferation of 
astrocytes. Furthermore, TNF-a selectively induced the mRNA and protein 
expressions of TNF-R2. The autocrine action of TNF-a was also demonstrated, as the 
expression of TNF-a gene was upregulated by exogenous TNF-a applied to the cells. 
Collectively, these findings indicate that TNF-a might stimulate the astrocyte 
proliferation via the induction of endogenous TNF-a and TNF-R2. 
Studies on the signal transduction of TNF-a showed that TNF-R2 played a 
major role in transducing the TNF-a signals to trigger the expression of TNF-a and 
TNF-R2 genes. Moreover, their upregulations were mediated by protein kinase C 
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(PKC) as phorbol 12-myristate 13-acetate (PMA) stimulated their mRNA expression, 
while selective PKC inhibitor, Ro-31, reduced the TNF-a-induced TNF-a and 
TNF-R2 mRNA levels. 
Interactions between TNF-a and p-adrenergic mechanism were demonstrated. 
It was observed that isoproterenol suppressed the TNF-a-induced proliferation of 
astrocytes, while propranolol, did not have significant effect on the cell proliferation. 
These findings indicate that the TNF-a-induced astrocyte proliferation is suppressed 
by p-ARs activation. On the other hand, TNF-a stimulated the mRNA and protein 
expressions of p-ARs in dose- and time-dependent manners. Moreover, propranolol 
applied to the astrocytes enhanced the TNF-a-induced TNF-a and TNF-R2 genes 
expression. 
It was observed that TNF-a induced the synthesis of different transcription 
factors, which can be considered as third messengers to transduce the signals of 
TNF-a. Our preliminary results showed that TNF-a upregulated the expression of 
transcription factors, c-fos, c-jun and nuclear factor-kappa B (NFKB) in astrocytes. On 
the other hand, TNF-a induced the expression of inducible nitric oxide synthase 
(iNOS) gene via TNF-R2, the TNFR subtype mediating astrocyte proliferation. 
However, the possible role played by iNOS in astrogliosis is still unclear. Moreover, it 
was observed that the TNF-a-induced iNOS gene expression was regulated by p-AR. 
Apart from TNF-a, interleukin-1 (IL-1) was also shown to stimulate the 
proliferation of astrocytes as well as the expression of endogenous TNF-a, P-AR and 
iNOS genes, which were also activated by TNF-a. On the other hand, another 
pro-inflammatory cytokine, IL-6 was ineffective to stimulate the astrocyte 
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CHAPTER 1. INTRODUCTION 
1.1. Events happened after brain injury 
Brain injury can generally be divided into two major types, ischemic and 
traumatic; the former is caused by obstruction of cerebral blood flow or nutrients 
supply, whereas the latter is due to mechanical insults. Whenever the central nervous 
system (CNS) is damaged, it undergoes a series of injury responses that typically 
include increase in inflammatory responses, acute or delayed neuronal and glial cell 
death, invasion of blood-bome leukocytes and formation of glial scars (Bush et al., 
1999; Benveniste, 1997b; Feuerstein et al., 1997). Nowadays, therapeutic drugs 
including calcium channel blockers, corticosteroids (Clausen and Bullock, 2001) and 
anti-inflammatory agents (Barone and Parsons, 2000) are not very effective in treating 
brain injury because of the lack of efficient drug delivery system and narrow 
therapeutic time window (Barone and Feuerstein, 1999). In addition, the complex 
brain structure and complicated structural and biochemical changes that occur after 
injury often increase the difficulties in pharmacological manipulation of the brain 
injury (Barone and Feuerstein, 1999). 
The brain is a particularly fragile organ; therefore, minor injury can cause 
permanent damage. Normally, the brain is protected by the skull, the cerebrospinal 
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fluid, the meninges and the blood-brain-barrier (BBB). Among these barriers, the 
BBB is the most important as it prevents the entry of hydrophilic substances and only 
small hydrophobic molecules can diffuse across the BBB. In injured brain, loss of 
BBB integrity is commonly observed, leading to the influx of water and electrolytes 
and subsequent swelling of glia and brain edema (Norenberg, 1994; Kimelberg, 1992). 
Besides, Reichenbach (1989) suggested that astrocyte swelling might be a cellular 
proliferation signal and a critical factor of astrogliosis. 
Following the breakdown of the BBB, blood-bome macrophages and 
leukocytes invade and elicit inflammatory responses. In fact, adhesion molecules and 
chemokines are expressed in the injured brain to facilitate the migration of these 
invaders across the BBB (Pantoni et al., 1998; Kim, 1996). The major factors secreted 
by them are inflammatory cytokines, which are diverse protein families produced in 
response to various immunogenic stimuli. The observation that elevated levels of 
cytokines in neurological diseases has recently been reviewed (Wang and Shuaib, 
2002; Zhao and Schwartz 1998; Arvin et al., 1996). For example, pronounced 
increase in both interleukin-1 (3 (IL-1 (3) mRNA and protein were detected after 
experimental brain injury (Fassbender et al., 2000; Fan et al., 1996a). Besides, tumor 
necrosis factor-a (TNF-a) level was elevated in both traumatized and 
non-traumatized brain regions (Fan et al., 1996b) and in cerebrospinal fluid (CSF) 
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(Selmaj et al., 1991). These cytokines have been reported to trigger astrogliosis, 
oxidative stress (Chan, 2001; Lewen et al, 2000) and the programmed cell death 
(Mattson and Scheff, 1994). 
In addition to inflammation, loss of the extracellular homeostasis can cause 
many deadly events, such as glutamate excitotoxicity via NMDA receptor activation 
and proteolytic degradation of structural and functional proteins by calcium-activated 
proteases (Zipfel et al, 2000; Upton and Rosenberg, 1994; Norenberg, 1994). 
Astrogliosis (reactive gliosis), a resulting process of astrocyte proliferation, 
has been suggested to hinder the regeneration of neuron by the formation of glial scars 
and production of inhibitory molecules (Fawcett and Asher, 1999). These had led to 
the thought that neurons could not regenerate after damaged (Sivron and Schwartz, 
1995； Alonso and Privat, 1993). However, recent studies suggest that neurons could 
regenerate, provided that the unfavorable environments, such as glial scars, are 
removed or controlled (Li and Raisman, 1995). These studies emphasize the 
importance of regulating astrogliosis in the treatment of brain injury. 
1.2. Glial cells 
As glial cells are the major cell types in the CNS, their general properties are 
briefly described in this section. The first account of neuroglia was cited by Dutrochet 
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in 1824, who noticed the existence in the CNS of non-neuronal components made of 
spindle-shaped cells which were morphologically distinct from neurons (Benveniste, 
1997a). These cells were considered as a form of connective tissue within the CNS, 
and were called neuroglia, which means "nerve glue". There are two broad subtypes 
of glial cells: macroglia and microglia. The macroglia consists of oligodendrocytes 
and astrocytes (Benveniste, 1997a). The basic properties of these cell types are 
described below. 
1.2.1. Microglia 
Microglia,,the resident macrophages of the brain, comprise 10-20% of total 
glial cells. Three forms of microglial cells, resting, activated, and reactive microglia 
are classified based on morphological and pathophysiological studies. Microglia 
express complement receptor for C3b, esterase and agglutinin-120, which are their 
common markers. However, these markers are nonspecific to microglia that they can 
also be found in other cell types (Benvensite, 1997a). 
Microglia have been thought to be the immune cells type resides in the CNS 
(Benveniste, 1997b) because they can perform functions like phagocytosis, antigen 
presentation, and production of cytokines, complement factors, proteases and 
oxidative radicals (Gehrmann et al, 1995; Banati et al., 1993). In inflammatory 
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conditions, the microglia become activated and can proliferate to form microglial 
nodules as seen in patients with viral encephalitis and AIDS dementia (Price et al., 
1988). Actually, microglia are also associated with normal physiology of the brain 
(Nakajima and Kohsaka, 1993). 
1.2.2. Oligodendrocytes 
Oligodendrocytes arise from oligodendrocyte-type-2A progenitor cells and 
they are the myelin-forming cells in the CNS. Myelin sheaths extended from the cell 
bodies of oligodendrocytes wrap around axons in a spiral manner and facilitate 
efficient nerve impulses conduction. Individual oligodendrocyte is capable of 
wrapping numerous adjacent axons. Myelin is composed of 70-85% lipid and 15-30% 
protein. The most commonly used marker for oligodendrocyte identification is 
galactocerebroside, the major glycolipid of myelin (Benveniste, 1997a). Other 
markers are myelin basic protein and 2', 3'-cyclic nucleotide 3'-phosphohydrolase. 
Both of them have been shown to regulate myelination (Readhead et al., 1990). 
1.2.3. Astrocytes 
Astrocytes, named for their starry shape, display an extensive variety of sizes 
and shapes. Two major types of astrocytes, protoplasmic astrocytes and fibrous, are 
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classified according to their differences in developmental, histological and 
biochemical properties, antigenic characteristics, and localizations in the CNS 
(Levison and Goldman, 1993; Miller and Raff, 1984). The protoplasmic astrocytes are 
characterized by highly branched processes forming membranous sheets and are 
localized mainly within gray matter. The fibrous astrocytes, in contrast, possess 
relatively long processes with fewer branches and are predominantly found in white 
matter (Levison and Goldman, 1993). 
There are several biochemical characteristics that define astrocytes in the 
mammalian CNS. The most common one is the cytoplasmic inclusion of 8-9 nm 
intermediate filaments whose major component is a 49 kda protein, the glial fibrillary 
acidic protein (GFAP) (Goldman et al, 1978). Astrocytes also express other 
intermediate filaments like vimentin and nestin. Other markers such as 
calcium-binding protein S-100 and glutamine synthetase have also been used as 
additional aids in defining astrocytes in the CNS (Ghandour et al., 1981; Norenberg 
and Martinez-Hernandez, 1979; Isobe and Okuyama, 1978; Moore, 1965). The 
presence of these two proteins suggests that astrocytes may play important roles in 
glutamate metabolism and calcium homeostasis. 
In the past, astrocytes have been assumed to serve as no more than passive 
physical support elements for neurons; however, this point of view has given way as 
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advances in cell biology have made it possible to understand their functions better. It 
is now clear that astrocytes have key roles in brain function, development and disease. 
It has been claimed that the brain will never be fully understood without an 
understanding of the many functions of astrocytes (Kimelberg and Norenberg, 1989). 
Some of their general functions are summarized below. 
1.2.3.1. Uptake of neurotransmitters 
Astrocytes take part in the removal of neurotransmitters released into synaptic 
clefts by neurons and this process plays an important role in terminating synaptic 
transmission. One^ of the neurotransmitters being removed is glutamate, which is 
released at excitatory glutamatergic synapses. Glutamate is transported into astrocytes 
by a high-affmity uptake system and converted by glutamine synthetase into 
glutamine before being recycled back to neurons (Benveniste, 1997a). This process is 
particularly important as excessive extracellular glutamate can lead to activation of 
NMDA receptors present within synaptic membranes, leading to increase in calcium 
influx and eventually excitotoxicity (Upton and Rosenberg, 1994). Besides, 
astrocytes can metabolize inhibitory neurotransmitter y-aminobutyric acid (GABA) 
via the action of GABA transaminase (Hansson et al., 1984). 
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1.2.3.2. Maintenance of extracellular homeostasis 
Astrocytes help to maintain the homeostasis of the extracellular fluid in the 
brain. Electrical activity of neurons leads to the release of K+ into the extracellular 
space where, as a consequence, the K+ concentration increases. This increase may 
cause severe alterations in neuronal excitability. Therefore, astrocytes take part in the 
K+ buffering systems (Bevan et al., 1985; Newman, 1984). In addition, the 
extracellular pH may change during neuronal activity and in pathological situations; 
and the pH changes can interfere cerebral blood flow. Astrocytes have been suggested 
to stabilize extracellular pH via Na+/H+ exchange and Na^/HCOs" cotransport (Schlue 
et al. 1991). Indeed, it has been suggested that astrocyte-mediated vasodilation has 
been shown to be one of the mechanisms of coupling neuronal activity to blood flow 
(Parri and Cmnelli, 2003). Astrocytes are also involved in the regulation of 
extracellular calcium and sodium ions (Clausen, 1992). 
1.2.3.3. Induction of blood-brain-barrier 
‘ Moreover, astrocytes are crucial in maintaining the integrity of the BBB by 
wrapping their cell processes around the brain blood capillaries and controlling the 
substances entering and leaving the CNS. The capillary endothelial cells in the brain 
are joined together by tight junctions to form the BBB; therefore, the BBB is virtually 
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impermeable to most substances. Studies on glial-BBB relationship have reported that 
astrocytes regulated the tight-junction formation between endothelial cells (Wolburg 
et al., 1994) and increased BBB permeability during focal cerebral ischemia (Yang et 
al., 1999). These indicate that interaction exists between astrocytes and endothelial 
cells in the control of the BBB function. 
1.2.3.4. Guidance of migrating neurons during development 
Migration of immature neurons to the gray matter during neurogensis is 
guided by radial glia (Rakic, 1971). Radial glia are a form of astrocyte, which arise at 
embryonic stage during brain development, and after neurogensis is completed, they 
become transformed into astrocytes (Schmechel and Rakic, 1979). It is thought that 
adhesion molecules present on radial glia surface guide neurons to migrate to their 
appropriate locations in the CNS (Benveniste 1997; Choi and Lapham, 1976). 
1.2.3.5. Immunocompetent cells of the brain 
The immunological events occur in the CNS have been shown to be partly 
contributed by astrocytes. They can produce and respond to cytokines like 
interleukins, tumor necrosis factors, transforming growth factors and colony 
stimulating factors to affect growth and differentiation of lymphocytes and 
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macrophages. These suggest that astrocytes can interact with peripheral immune 
system in body defense (Benveniste, 1997). In addition, they may function as 
antigen-presenting cells in the CNS as they can be induced to express major 
histocompatibility antigens (Benveniste, 1997a). 
1.2.3.6. Contribution to astrogliosis 
Astrogliosis is an early event that is detectable several days after brain injury, 
reaches its maximum after 3-4 weeks and subsides over subsequent weeks or months 
(Amaducci et al” 1981). This process is characterized by cellular hypertrophy and 
thickening of cytoplasmic processes of astrocytes, along with the GFAP 
overexpression. While the pathological significance of GFAP overexpression is not 
fully understood, animal infused with GFAP antisense oligonucleotides showed both 
decreased GFAP immunostaining and reduced hypertrophy at the injured region (Eng 
et al., 2000); this reveals its prominent role in, or close relationship to, astrogliosis. 
Astrogliosis is usually followed by scars formation that has been shown to 
‘block axons to regenerate. Scars consist of proliferated astrocytes bound firmly by 
interwoven processes connected together by tight junctions, so axons cannot penetrate 
this compact barrier (Fawcett and Asher, 1999). In addition to this barrier, reactive 
astrocytes secrete proteoglycans like chondroitin sulphate proteoglycan (CSPG) to 
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further inhibit the growth of neurons (Fawcett and Asher, 1999). Reducing CSPG 
synthesis with proteoglycan degrading enzymes (Morgenstem et al., 2002) and 
ablating the scars by injecting glutamate homologue (McGraw et al., 2001) have been 
demonstrated to promote axon regrowth. 
On the other hand, the forming of glial barrier around the injured site has been 
thought to be advantageous because the scars can isolate the still intact CNS tissue 
from secondary lesions (Fitch and Silver, 1997). This hypothesis is further supported 
by in vitro studies that reactive astrocytes secreted neurotrophic factors to support 
neuron regrowth (Merrill and Benveniste, 1996; Strauss et al, 1994). 
Therefore, understanding the steps leading to astrogliosis should be crucial to 
explain these apparently conflicting hypotheses. 
1.3. Cytokines and astrogliosis 
Astrogliosis is likely to be the universal reaction implicated in any type of 
neurological diseases, including multiple sclerosis (MS), experimental allergic 
’encephalomyelitis, Parkinson's, Alzheimer's, Huntington's and Down's diseases 
(Calne, 1994). As astrocyte proliferation is one of the steps in astrogliosis, the factors 
that stimulate astrocyte proliferation have been under intense investigation, and the 
suspected ones include neurotransmitters, neuropeptides, cytokines and growth factors 
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(Mantyh et al., 1995; Beaujouan, 1991; Richardson et al., 1988; Giulian and Lachman, 
1985). Among these factors, we focused mainly on cytokines because of their 
remarkable effects on glial cells activation (John et al.’ 2003). Among the cytokines, 
pro-inflammatory cytokines are believed to serve as important mediators in the 
initiation and propagation of CNS damage. Interleukin-6 (IL-6), IL-1, 
interferon-gamma (IFN-y) and TNF-a are the major cytokines released during brain 
inflammation (Wang and Shuaib, 2002; Arvin et al., 1996; Woodroofe, 1995; 
Rothwell et al., 1993). However, the role played these cytokines in astrogliosis is still 
unclear. 
1.3.1. IL-6 and astrogliosis 
IL-6, a 26 kda polypeptide, is produced mainly by astrocytes, microglia and 
macrophages following brain injury. In general, it functions prominently to induce the 
terminal differentiation of activated B cells into immunoglobulin-secreting plasma 
cells. In astrocytes, IL-6 is mitogenic both in vitro and in vivo, (Balasingam et al., 
1994; Selmaj et al, 1990) and is believed to contribute to reactive gliosis. However, 
Klein et al,, (1997) suggested that IL-6 could only change the morphology of 
fibrillary astrocytes but did not play an active role in proliferation as no increase in 
GFAP immunoreactivity was observed. In contrast, reactive astrocytes can produce 
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IL-6 and stimulate themselves to secrete nerve growth factor (NGF), which in turn 
induces the differentiation of neurons (Aschner, 1998; Benveniste et al., 1990). These 
suggest that IL-6 may have dual role in brain injury; therefore, its effects on 
proliferation and other actions in astrocytes were examined in my study. 
1.3.2. IL-1 and astrogliosis 
Two forms of IL-1, IL-1 a and IL-1 (3, are produced by astrocytes, microglia 
and blood-bome immune cells in response to various stimuli, such as endotoxin and 
cytokines. IL-1 may take part in astrogliosis directly by stimulating astrocyte 
proliferation, differentiation and maturation (Giulian and Lachman, 1985). Indeed, 
when injected into the CNS, IL-1 promotes astroglial scars formation and astrogliosis 
(Giulian et al, 1988). This cytokine could also trigger other inflammatory responses as 
it can augment arachidonic acid production and nitric oxide (NO) synthesis (Rothwell 
and Relton, 1993). In contrast to the detrimental side, it is reported that IL-1 induced 
cultured astrocytes to synthesize and release NGF and basic fibroblast growth factor, 
which may rescue the damaged neurons in the early phase of brain injury (Yoshida 
and Toya, 1997). 
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1.3.3. IFN-y and astrogliosis 
IFN-y is a 17 kda polypeptide produced primarily by CD4+ and CD8+ T cells. 
Different from IL-6 and IL-1, IFN-y is normally not expressed in the brain and 
breakdown of BBB allows activated T cells to invade and produce it. This cytokine 
enhances expression of MHC class I and class II antigens on astrocytes. Moreover, it 
primes astrocytes for the production of NO, cytokines and complement factors, which 
can lead to inflammatory and cytotoxic events (Aschner, 1998; Benveniste, 1997a). 
1.3.4. TNF-a and astrogliosis 
TNF-a is o.verexpressed in various pathological conditions, such as parasitic 
diseases, bacterial infections, trauma and ischemia (Feuerstein et al., 1994). For 
example, systemic kainic acid, a cytotoxin, administration increases TNF-a mRNA 
expression in the brain (Minami et al, 1991) and intracerebroventricular LPS 
injection stimulates TNF-a protein expression (Siren et al., 1992). TNF-a has been 
thought to be one of the major factors that induce astrogliosis (Selmaj et al., 1990). 
For example, TNF-a is found in the CSF, the MS plaque regions and the astrocytes in 
MS patients (Selmaj et al., 1991); reactive astrocytes produce TNF-a after closed 
head injury (Shohami et al., 1997); microinjection of TNF-a causes astrogliosis in 
neonatal mouse brain (Balasingam et al, 1994), and TNF-a induced overexpression 
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of GFAP in cultured astrocytes (Zhang et al, 2000). The above clearly indicates that 
TNF-a is the cytokine particularly related to astrogliosis. The physiological TNF-a 
level is low (i.e. ranging from undetectable to 20 pg/mg protein); however, it could be 
induced to be above 200 pg/mg protein during brain injury (Saito et al, 1996; 
Shohami et al, 1996). 
Moreover, other studies have shown that blocking TNF-a action improves the 
outcome of brain injury. For example, antibodies and antisense oligonucleotides 
against TNF-a have been demonstrated to reduce edema and cell death, and attenuate 
BBB disruption after brain injury (Mayne et al., 2001; Shohami et al., 1996). Hence, 
controlling the TNF-a production and/or secretion maybe a potential strategy to 
reduce astrogliosis and offer more effective treatments for brain injury. Therefore, we 
concentrated mainly on this cytokine in the present study. 
1.3.4.1. General properties of TNF-a 
In mammals, TNF-a (cachectin) is produced mainly by activated macrophages 
expressed as a 26 kda transmembrane precursor following their induction by diverse 
groups of substances, including mitogens, cytokines, endotoxin, parasites and viruses 
(Manogue et al., 1991). The 26 kda precursor can be enzymatically cleaved into a 17 
kda soluble form, which can trimerize to form a 52 kda physiological and functional 
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unit (Manogue et al” 1991). This cytokine participates in a wide range of biological 
activities that its immunomodulatory, anti-tumor, mitogenic and anti-viral properties 
have been documented (Barone and Feuerstein, 1999; Shohami et al., 1999; Ruby et 
al； 1997). In the CNS, TNF-a plays both immunological and developmental roles. 
For example, TNF-a stimulates p-endorphin and prolactin release from cultured 
pituitary cells, suggesting that it is important in normal endocrinal axis 
(Ricciardi-Castagnoli et al., 1990). Moreover, TNF-a induces other cell types, 
including astrocytes, to produce IL-1, IL-6 and TNF-a itself (Benveniste and Benos, 
1995). 
In contrast,to the detrimental effects of TNF-a, recent studies suggest a 
protective role of TNF-a. For example, mice lacking TNFR showed a larger infarct 
area after middle cerebral artery occlusion (MCAO) (Bruce et al, 1996) and 
pre-treating mice with 0.5 i^g TNF-a significantly reduce the severity of the focal 
MCAO ischemia (Nawashiro et al., 1997). This protection maybe linked to the ability 
of TNF-a to induce antioxidative enzyme, manganese superoxide dismutase 
(MnSOD), which removes oxygen radicals and protects against oxidative stress and 
lipid peroxidation (Braughler and Hall, 1992; Wong and Goeddel, 1988). Moreover, 
TNF-a activates other protective mechanisms, such as ceramide pathway (Ginis et al, 
1999). 
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1.3.4.2. TNF receptors (TNFRs) 
TNF-a must bind to TNF receptors (TNFRs) to exert its effect. Two 
immunologically distinct TNFRs, namely TNFR type-1 (TNF-Rl; p55) and TNFR 
type-2 (TNF-R2; p75), have been identified (Tartaglia and Goeddel, 1992). Their 
extracellular regions contain four conserved cysteine-rich repeat with 28% homology, 
whereas almost no homology can be found between their intracellular domains. These 
suggest that they utilize different signaling pathways and mediate different functions 
(Goeddel et al., 1986; Grell et al, 1994). In addition, TNF-P (lymphotoxin) also binds 
the TNFR at very high affinity (Orlinick and Chao, 1998). 
The intracellular region of TNF-Rl, but not TNF-R2, has been mapped to a 
death domain, which once activated, recruits and subsequently activates caspases to 
initiate apoptosis (Natoli et al., 1998; Hsu et al, 1996). In contrast, other studies 
found that TNF-R2 activation contributes to thymocytes and T cells proliferation, and 
the alteration of the genes expression pattern (Grell et al, 1998; Tartaglia et al, 1993). 
In addition, MacEwan (2002) proposed that events triggered by this cytokine are 
determined by the relative densities of the two subtypes on cell surface. Although our 
previous studies found that astrocytes have both receptor subtypes (Lung et al., 2001), 
their roles in apoptosis and proliferation in astrocytes are still unclear. Moreover, both 
receptors lack intrinsic catalytic domains (MacEwan, 2002) that they require 
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intracellular proteins to transduce their signals; however, the signaling pathway in 
astrocytes is still not fully understood. However, some of established signals 
mediating TNF-a actions in other cell types are described below. 
1 .3 .4 .3 . N F K B induction 
In most cell types, TNFRs, once activated, can recruit intracellular adaptor 
protein TNF receptor-associated factors (TRAFl and TRAF2) to their cytoplasmic 
regions (Wajant et al, 1999; Rothe et al., 1994), and finally transduces signal to 
activate nuclear factor-kappa B (NFKB) (Wajant and Scheurich, 2001). NFKB, a 
dimeric transcription factor, is composed of p50 and p65 (RelA) subunits, which once 
activated, the dimer translocates to nucleus, binds to c/5-acting sequence and regulates 
transcription of target genes (Wang and Baldwin, 1998). 
Recent reviews suggested that N F K B controls apoptosis and proliferation. For 
example, N F K B activates the expression of antiapoptotic proteins, including MnSOD 
and Bcl-2 (Karin and Lin, 2002). NFKB-knockout fibroblasts are more susceptible to 
the apoptosis induced by T N F - a and overexpressing N F K B reduces the severity of 
apoptosis (MacEwan, 2002; van Antwerp et al., 1998; Liu et al., 1996). Moreover, 
Kirillova et al (1999) demonstrated that N F K B is involved in the D N A replication 
induced by TNF-a in hepatic cells. In astrocytes, however, the role of this 
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transcription factor in cell survival control is not known. 
1.3.4.4. Intermediate early genes 
Intermediate early genes (lEGs), which encode transcription factors proteins, 
are rapidly induced upon stimulation without de novo protein synthesis, the specific 
characteristic of these genes (Herdegen and Leah, 1998). lEGs are crucial in both 
normal and pathological functions of the nervous system (Herdegen and Leah, 1998; 
Hughes et al., 1999). Among the lEGs, c-fos and c-jun are particularly important 
owing to their immediate inductions after brain injury (Herdegen and Waetzig, 2001). 
For example, the expression of both GFAP and c-fos were increased after cryogenic 
brain injury (Cook et al, 1998) and in cerebral ischemia (Akins et al, 1996). 
Therefore, lEGs and astrogliosis are closely related. 
c-jun and c-fos are induced by various growth factors and cytokines. c-Fos and 
c-Jun are their encoded oncoproteins that they can dimerize to form transcription 
factor, activator protein-1 (AP-1) (Angel and Karin, 1991). The deregulation of them 
can cause neoplastic transformation. Moreover, antisense oligonucleotides and 
antibodies against their mRNA and protein inhibited the proliferation of fibroblasts 
(Holt et al., 1986) and erythroleukemia cells (Smith and Prochownik, 1992). This 
suggests that they are important in the control of cell survival and cell death. However, 
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the outcome of AP-1 activation seems to be cell type specific. While it promotes 
apoptosis in some cell types, it is required for the survival for others (Shaulian and 
Karin, 2001). In astrocytes, the role of AP-1 in cell proliferation is not known, so 
these two lEGs were included in this study. 
1.3.4.5. iNOS is the target of N F K B and AP-1 
One of the targets of N F K B and AP-1 is inducible nitric oxide synthase (iNOS) 
(Nishiya et al., 2000; Eberhardt et al, 1996), which utilizes L-arginine and molecular 
oxygen as starting materials to synthesize nitric oxide (NO), a reactive radical taking 
part in diverse biological responses including vasodilation, neurotransmission, 
immune responses and diseases (Canals et al, 2001). In fact, molecular cloning has 
identified three distinct NOS isoforms that the inducible form (iNOS), once activated, 
has capability to generate larger amount of NO than the constitutive forms for hours 
to days; therefore, it has been implicated in the CNS pathology (Orihara et al., 2001; 
Kristofer «/.,2001). 
Increased generation of NO has been observed in demyelinating diseases, 
Alzheimer's disease, cerebral ischemia and trauma (Murphy, 2000). In the case of MS, 
reactive microglia and macrophages do not show iNOS reactivity that is principally 
detected on reactive astrocytes in demyelinating plaques, co-expressing TNF-a 
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immunoreactivity (Bo et al., 1994; Brosnan et al., 1994). Therefore, it is interesting to 
find out the relationship between astrogliosis and NO. Recent studies reported that 
NO, at low concentrations, reduces apoptosis (Takuma et al, 2002; Torok et al., 2002). 
Moreover, it induces antiapoptotic molecules, such as Bcl-2 and MnSOD (Ciani et al, 
2002; Calabrese et al., 2000). These findings suggest that NO may have dual role in 
brain injury. Besides, elevated iNOS immunoreactivity accompanies regenerative 
processes was observed in rat ganglia (Magnusson et al., 1996)，and that NO donors 
stimulated neurogensis at subventricular zone in rat model (Zhang et al., 2001), 
further suggesting that NO is likely to have proliferative property. 
Taken together, detrimental or beneficial roles of NO may depend on the 
quantity and the critical time and space of its generation (Canals et al., 2001; ladecola, 
1997). 
1.4. P-Adrenergic receptors (P-ARs) 
In the CNS, a number of receptor systems, including adrenergic, cholinergic 
and amino acid receptors, have been identified to participate in many different 
functions of brain (Murphy, 1993). Among these systems, (3-adrenergic receptor 
(p-AR) is likely to be more important because of its influence on many 
neurophysiologies. For example, p-AR controls astroglial glycogen metabolism 
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(Rosenberg and Dichter, 1985), glial membrane potential (Walz, 1989), amino acid 
uptake (Hannson and Ronnback, 1992), neurotrophic factors production (Schwartz 
and Mishler, 1990)，and cytokines synthesis and release (Maimone et al., 1993; Norris 
and Benveniste, 1993). In disease condition, activating the p-adrenergic mechanism 
suppresses endotoxin-induced production of cytokines (Nakamura et al., 1998; van 
der Poll et al., 1996; Koff et al, 1986), protects cultured hippocampal cells from 
glutamate toxicity (Junker et al, 2002), reduces apoptotic cell death after transient 
ischemia (Zhu et al, 1999)，and promotes GFAP overexpression and astrogliosis 
(Hodges-Savola et al., 1996); these observations point to the importance of 
P-adrenergic system in normal and injured brain. 
1.4.1. p-ARs and astrogliosis 
It has been reported that p-AR regulates astrogliosis and probably the 
subsequent glial scar formation after neurological diseases; however, other signaling 
pathways, such as adenosine and purinergic receptors, are also involved (Brambilla et 
al., 1999; Abe and Saito, 1998). Notably, both resting and reactive astrocytes obtained 
from rat brain have been shown to express P-AR (Morin et al,, 1997; Sutin and Shao, 
1992; Salm and McCarthy, 1989; Trimmer and McCarthy, 1986). The participation of 
P-AR in astrogliosis has been shown in various in vivo studies. For example, 
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P-adrenergic activation increase GFAP immunoreactivity in the absence of injury, 
whereas blocking the p-AR greatly reduced the injury-induced astrogliosis 
(Hodges-Savola et al., 1996); p-AR blockade suppressed glial scar formation (Sutin 
and Griffith, 1993); circulating catecholamines levels and P-AR density were found to 
be elevated in brain injury (Mantyh et al., 1995; Hamill et al., 1987); and 
noradrenergic denervation reduced the number of reactive astrocytes (Griffith and 
Sutin, 1996). As mentioned before, as TNF-a also triggers astrogliosis and GFAP 
accumulation, (3-adrenergic mechanism and TNF-a may interact together in 
astrogliosis and astrocyte proliferation, perhaps through p-AR. 
1.4.2. General properties of P-ARs 
P-AR belongs to the G-protein-coupled superfamily of receptors that consists 
of a single polypeptide chain and contains seven transmembrane domains. Three 
principal types of P-AR are classified according to their differences in tissue 
distribution and pharmacological response (Johnson 1998; Minneman et al, 1981). 
Pi-AR localizes mainly in heart and cerebral cortex, whereas P2-AR predominates in 
vascular tissues and cerebellum. P3-AR is expressed in adipose tissues where it 
functions largely in the regulation of lipid metabolism, so it was not included in the 
present study (Minneman et al, 1981). Noradrenaline and adrenaline, the two 
• 2 3 
naturally found catecholamines, bind Pi-AR at similar affinity, whereas adrenaline 
binds P2-AR at higher affinity than noradrenaline. Moreover, various (3-agonists and 
-antagonists have been synthesized to bind different P-AR subtypes with differential 
affinities, leading to various degrees of activation or deactivation of p-AR subtypes 
(Emilien and Maloteaux, 1998). 
Upon the binding of P-agonist, P-AR is turned on. The activated P-AR recruits 
and activates a G-protein, and subsequently activates a number of intracellular 
messengers, which in turn stimulate various protein kinases, such as cAMP-dependent 
protein kinase (PKA) and protein kinase C (PKC), leading to subsequent 
phosphorylation of serine/threonine residues of target proteins (Fimia and 
Sassone-Corsi, 2001; de Blasi, 1990). Moreover, latest studies showed that p-AR 
could be coupled to MAPK/ERK cascades, which control cell proliferation via 
guanine nucleotide-exchange factors in cAMP-dependent or -independent manner 
(Crespo et al., 1995; Pak et al., 2002). Therefore, (3-adrenergic mechanism may 
associate with proliferation of astrocytes. 
1.4.3. Interactions between (3-adrenergic mechanism and TNF-a 
p-Adrenergic mechanism and TNF-a are very different parameters; however, 
interactions between TNF-a and p-AR have been found in peripheral tissues. For 
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example, p-adrenergic activation suppresses endotoxin-induced production of TNF-a 
in various tissues, such as kidney (Nakamura et al, 2000a), blood (Izeboud et al, 
1999) and heart (Smart et al, 2000); the inhibitory effect was reversed by 
p-antagonists. Moreover, in vitro studies suggested that the suppression on TNF-a 
was a consequence of MAPK inhibition and enhanced cAMP generation (Nakamura 
et al., 2003; Yoshimura et al., 1997). However, the underlying mechanism is still not 
fully known. At present, it is not clear whether (3-adrenergic mechanism and TNF-a 
action interact in the CNS, particularly in astrocytes. 
1.5. Aims and scopes of the project 
The CNS has traditionally been regarded as an immunologically privileged 
site. However, recent findings showed that astrocytes are able to produce and respond 
to cytokines like IL-1, IL-6, IFN-y and TNF-a. As described previously, insults to the 
CNS lead to astrogliosis and formation of astroglial scars that hinder neuron 
regeneration and remyelination. One of the major steps leading to astrogliosis has 
been thought to be astrocyte proliferation (Fawcett and Asher, 1999). 
Recently, it was found that TNF-a mRNA and protein were elevated and 
localized in reactive astrocytes after various neurological diseases, such as MS (Fan et 
al., 1996; Selmaj et al., 1991a; 1991b), suggesting that TNF-a may play an important 
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role in astrogliosis and possibly glial scarring observed after brain injury. Another 
related observation is that P-adrenergic mechanism has been found to regulate 
astrocyte proliferation and astrogliosis (Hodges-Savola et al., 1996; Sutin and Griffith, 
1993). These, together with the observation that regulation of TNF-a by P-AR has 
been found in peripheral tissues (Nakamura et al” 1999; 2000a; Izeboud et al., 1999; 
Smart et al., 2000)，suggest interactions exist between TNF-a action and P-adrenergic 
mechanism in the CNS. However, the relationship between TNF-a and P-AR in 
astrogliosis is still undefined. Thus, it is of importance to investigate their relationship 
in order to elucidate the signaling pathway mediating the effects of TNF-a and p-AR 
on astrogliosis. The long-term goal is to find better therapeutic treatments to improve 
the outcome of brain injury. 
In this study, primary astrocytes were obtained from neonatal rat brain cortex. 
Astrocytes cultured from neonatal rat cortex have advantages of reduced 
oligodendrocyte and neuron contaminations and they have higher growth rate 
(McCarthy and de Vellis, 1980). 
In the first set of experiments, the effects of TNF-a, as well as other 
pro-inflammatory cytokines (i.e. IL-1 a , IL-1 (3, IL-6 and IFN-y) on astrocyte 
proliferation were compared. We examined the effects of these cytokines because they 
are also elevated in injured brain. Then, the roles of each TNFR subtype on the 
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proliferation of astrocytes were examined by specific TNFR antibodies study. In fact, 
TNFR antibodies have been used as receptor agonists to elicit cellular responses 
(Grell et al., 1998; Tartaglia et al., 1991). On the other hand, the effects of p-agonist 
isoproterenol and P-antagonist propranolol on the proliferation of astrocytes were also 
examined. 
As various intracellular signaling and second messenger systems have been 
suggested to regulate the expressions of cytokines and the cytokine-induced responses, 
in the second set of experiments, the intracellular signaling pathway mediating the 
expressions of TNFRs and P-AR was studied. PKC is an intracellular signaling 
intermediate present in almost all cell types. Besides, altered PKC activity has been 
observed in brain injury (Padmaperuma et al., 1996; Yang et al, 1993); thus the PKC 
pathway was studied with the helps of specific activator, phorbol 12-myristate 
13-acetate (PMA) and selective inhibitor, 
3-11 -[3-(aniidinothio)propyl]-3-indoyl}-4-( 1 -methyl-3-indoyl)-1 H-pyrrole-2, 5-dione 
methanesulfonate (Ro-31). In addition, as addition of cAMP analogue changes the 
morphology of astrocytes resemble reactive astrocytes (McCarthy and de Vellis, 
1980), the actions of PKA activator and inhibitor were included in the present study. 
In the third set of experiments, the interrelationship between p-AR and TNF-a 
was examined. In this study, selective p-agonists and -antagonists were examined for 
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their effects on TNF-a and TNFR expressions. 
NO, generated by action of iNOS, has recently been reported to be an 
important second messenger (Canals et al, 2001) and cytokines are potent iNOS 
inducers (Munoz-Femandez and Fresno, 1998). However, conflicting results were 
obtained concerning the regulation of iNOS. For example, cAMP enhanced iNOS 
mRNA in rat mesangial cells but attenuated in other cell types (Beck et al., 1999; 
Pahan et al., 1997). The regulation of iNOS in astrocytes is still unclear; as a result, 
relationship between TNF-a, (3-AR and iNOS was examined in this set of 
experiments. As N O is a target of transcription factors N F K B and AP-1, these two 
transcription factors were also included in the present study. 
The major aim of this study is to elucidate the signaling pathways mediating 
astrocyte proliferation, an important step that leads to astrogliosis. Last but not least, it 
is hoped that the results obtained would provide valuable information on the 
regulatory mechanisms resulting in astrogliosis, and help to find a more effective 
treatment for brain injury. 
： ' 
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CHAPTER 2. MATERIALS & METHODS 
2.1. Materials 
2.1.1. Rats for astrocyte culture 
Newborn Sprague-Dawley rats were obtained from the Animal House at The 
Chinese University of Hong Kong. 
2.1.2. Cell culture materials 
2.1.2.1. Complete Dulbecco's Modified Eagle Medium:F12 (DF12) 
The Dulbecco's modified Eagle medium (DMEM):F12 powder (Invitrogen, 
Hong Kong) with HEPES buffer and L-glutamine was dissolved in 800 ml 
double-distilled water with 1.2 g sodium bicarbonate added. Then heat-inactivated 
fetal bovine serum (Invitrogen, Hong Kong), 10,000 U/ml penicillin, 10,000 ^ig/ml 
streptomycin, 25 |ag/ml fungizone (Invitrogen, Hong Kong) were added. The medium 
was made up to 1 litre, adjusted to pH 7.3 and filtered. The final medium contained 
10% (v/v) FBS, 100 U/ml penicillin, 100 |ig/ml streptomycin and 0.25 ^ig/ml 
fungizone. The filtered medium was stored at 4°C until use. 
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2.1.2.2. Phosphate buffered saline (PBS) 
Phosphate buffered saline (PBS) was prepared by dissolving a pack of 
powdered Dulbecco's PBS (Invitrogen, Hong Kong) in 800 ml of double-distilled 
water, adjusted to pH 7.4 and made up to 1 litre, then autoclaved. 
2.1.3. Drugs preparation 
2.1.3.1. Recombinant cytokines 
Recombinant mouse TNF-a (specific activity: 6 x 10^ U/mg), mouse IL- la 
(specific activity: 5 x 10^ U/mg), mouse IL-ip (specific activity: 5 x 10? U/mg), 
mouse IL-6 (specific activity: 1 x 10^ U/mg), and mouse IFN-y (specific activity: 1 x 
U/ml) were and purchased from Roche, Germany. All cytokines were stored in 
aliquots at -20°C until use. These cytokines have been reported to be active in 
cultured rat astrocytes (Lung et al., 2001; Chang et al., 2001). 
2.1.3.2.-Modulators of protein kinase A (PKA) 
PKA activator, dbcAMP (Sigma, U.S.A.) was dissolved in complete medium, 
while selective PKA inhibitor (Simmons and Murphy, 1994), 
N- {2-[(/?-bromocinnamyl)amino]ethyl}-5-isoquinolinesulfonamide (H89; Calbiochem, 
• 3 0 
U.S.A.) was dissolved in absolute ethanol. Both modulators were stored at -20°C until 
use. 
2.1.3.3. Modulators of protein kinase C (PKC) 
PKC activator, PMA (Sigma, U.S.A.) was dissolved in absolute ethanol. PKC 
inhibitor, Ro 31 (Calbiochem, U.S.A.) was dissolved in dimethyl sulfoxide (DMSO). 
All PKC modulators were stored in aliquots at -20°C and reconstituted with complete 
medium before use. Both modulators have been reported to be active in cultured rat 
astrocytes (Chen et al., 1998; Abe and Siato, 2000). 
2.1.3.4. p-Agonists and -antagonists 
The common P-AR agonist, isoproterenol (ISO), and common p-AR 
antagonist, propranolol (PROP); pi-AR agonist, dobutamine (DOB), and Pi-AR 
antagonist, atenolol (ATEN); f>2-AR agonist procaterol (PROC), and p2-AR antagonist, 
ICI 118, 551 (ICI) (Emilien and Maloteaux, 1998) were purchased from Sigma, U.S.A. 
and dissolved in complete medium and stored in aliquots at -20°C until use. 
2.1.3.5. Antibodies used in western blot analysis 
Goat anti-TNF-Rl polyclonal, mouse anti-TNF-R2 monoclonal, rabbit 
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anti-PiAR polyclonal, rabbit anti-PzAR polyclonal, rabbit anti-c-Fos polyclonal, 
rabbit mt\-c-Jun polyclonal primary antibodies were purchased from Santa Cruz, 
U.S.A. HRP-labeled goat anti-rabbit, goat anti-mouse and rabbit anti-goat secondary 
antibodies were purchased form Zymed Laboratories, U.S.A. 
2.1.4. Reagents for cell proliferation determination 
Reagents used for [^H]-thymidine incorporation assay included 
[^H]-thymidine (specific activity: 2 Ci/mmol; Amersham, UK), trichloroacetic acid 
(Sigma, U.S.A.) and liquid scintillation cocktail (PerkinElmer, U.S.A.). 
Thiazolyl blue tetrazolium bromide (MTT) used in the MTT assay was 
purchased from Sigma, U.S.A. 
2.1.5. Reagents for RNA isolation 
TRIzol reagent (Invitrogen, Hong Kong) and isopropanol were stored at 4 T , 
while chloroform and ethanol were stored at room temperature until use. 
2.1.6. Reagents for reverse transcription-polymerase chain reaction (RT-PCR) 
Reagents used for reverse transcription (RT) included: deoxynucleotide mix 
(dNTP, 10 mM each dNTP), AMV reverse transcriptase (25 U/|al), RNase inhibitor 
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(50 U/fil), random primer p(dN)6 (2 |ag/ml), magnesium chloride (25 mM). These 
reagents were purchased from Roche, Germany. Nuclease free water was purchased 
from Promega, U.S.A. Reagents used for polymerase chain reaction (PGR) included: 
deoxynucleotide mix (dNTP, 10 mM each dNTP; Roche, Germany), Tag DNA 
polymerase (5 U/|al; Promega, U.S.A). Specific sense and antisense primers were 
designed using information obtained from GenBank Sequence Database. All primers 
were synthesized by TechDragon, Hong Kong. Tris-ethylenediaminetetraacetic acid 
disodium salt (TE) buffer was used to reconstitute and dilute the PGR primers. The 
TE buffer contained 10 mM Tris (pH 8.0) and 1 mM ethylenediaminetetraacetic acid 
disodium salt (EDTA); these chemicals were purchased from Sigma, U.S.A. 
2.1.7. Reagents for Electrophoresis 
„ 6X DNA loading buffer contained 30% (v/v) glycerol, 0.25% (w/v) 
bromophenol blue and 36 mM EDTA (pH 8.5). 5X Tris-boric-EDTA (TBE) buffer 
was prepared by dissolving 54 g Tris base, 27.5 g boric acid and 3.72 g EDTA in 1 
liter double-distilled water, and the pH was adjusted to 8.3. The 100 bp DNA ladder 
marker was purchased from Invitrogen, Hong Kong. 
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Table. 2.1. Primers used in RT-PCR and the predicted sizes of the PGR products. 
cDNA Primer sequences (5，to 3，) Position Product size (bp) 
Sense strand: 
^ • tga gac ctt caa cac ccc ag 2166-2185 
p-Actin 201 
Antisense strand: 2343 2366 
ttc atg agg tag tct gtc agg tcc  
Sense strand: 
r. 1 acc aag tgc cac aaa gga acc 415-435 
丄 322 
Antisense strand: "714 
tac aca egg tgt tct gtt tct cc 
Sense strand: 
0 o atg aga aat ccc agg atg cag 2-22 
丄 IN卜K2 252 
Antisense strand: 232 253 aca gac gtt cac gat gca ggt g 
Sense strand: 




cag cac ttg "ggg teg ttg tag cac c  
Sense strand: 
p A r gcc age ate gag acc ctg 355-372 
2 Antisense strand: 789 810 ^兄 
ttt gtg ctc ttt caa gca gaa c 
Sense strand: 
tcc caa caa gga gga gaa att 171-192 
TNF-a 411 
Antisense strand: 560 581 
— tea tac cag ggc ttg age tea g 
Sense strand 
ctg caa gat ccc caa tga cc 743-762 
c-fos 273 
Antisense strand: 996 1015 
gaa tcc aca tct ggc aca ga 
Sense strand 
get tct ctc tag tgc tcc gta a 1248-1260 
^-Jun 427 
Antisense strand: 1653-1674 
caa cca gac ggg agg gac ta 
Sense strand: 
NFKB/P50 4-23 823 
I gag att ctg aat ccc cct ga  
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Antisense strand: om on, 
oU /-ozo 
ttc cag ccg eta tgt gta ga 
Sense strand 
ctc ctt caa aga ggc aaa aat a 468-489 
iNUS 73Q 
Antisense strand , , 11 八， 
1 loU-1197 
cac ttc ctc cag gat gtt gt 
2.1.8. Reagents and buffers for western blotting 
RIPA buffer contained 1% (v/v) Nonidet P-40 (Promega, U.S.A.), 0.5% (w/v) 
sodium deoxycholate (Sigma, U.S.A.) and 0.1% (w/v) sodium dodecyl sulfate (SDS; 
Sigma, U.S.A.) in IX PBS. Protease inhibitors were freshly prepared by dissolving 1 
tablet of protease inhibitors cocktail (Roche, Germany) per 10 ml RIPA buffer. 
Phenylmethylsulfonyl fluoride (PMSF) was purchased from Sigma, U.S.A. 
2X loading buffer contained 0.5 M Tris, pH 6.8, 10% (v/v) glycerol, 2% (w/v) 
SDS, 5% (v/v) 2-P-mercaptoethanol and 0.03% (w/v) bromophenol blue. IX running 
buffer was made up of 25 mM Tris, 192 mM glycine and 0.1% (w/v) SDS. Transfer 
buffer contained 39 mM glycine, 48 mM Tris, 0.037% (w/v) SDS and 20% (v/v) 
methanol. Blocking buffer was freshly prepared by dissolving 5% non-fat dried milk 
powder in PBS with 0.05% (v/v) Tween®20 (Sigma, U.S.A.) added. Washing buffer 
contained PBS with 0.1% (v/v) Tween®20. Western blotting detection reagents 
(ECL+Plus) were purchased from Amersham, UK. 
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2.2. Methods 
2.2.1. Preparation of primary astrocytes 
Astrocytes were extracted from cerebral cortex of newborn Sprague-Dawley 
rats as described before (Chang et al., 2001). Briefly, rat cerebral cortex were isolated 
and cut into I n W pieces under aseptic conditions. Then, 0.125% trypsin-EDTA (v/v) 
o 
was added and incubated at 37 C for 15 minutes, then dispersed with the help of a 19 
Gauge needle and passed through a 70 |im nylon mesh (Spectrum Laboratories, 
Canada). Cells were seeded at a concentration of 2x10^ per 75 cm^ culture flask and 
incubated at 37°C in an incubator supplemented with 5% CO2. The medium was 
changed at least twice a week. After 10 days, cells were shaken at 180 rpm at 37°C on 
an orbital shaker for 18 hours to remove oligodendrocytes (McCarthy and de Vellis, 
1980). The astroglial culture consisted of greater than 90% GFAP-positive cells as 
revealed by GFAP-immunostaining. 
2.2.2. Preparation of cells for assays 
All samples for cell proliferation, RT-PCR and Western blotting assays were 
performed with cells around 21 days post dissection. In these experiments, cells were 
seeded either on 96 well-plates or in 100 mm petri dishes in complete medium. 
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2.2.3. Determination of cell proliferation 
2.2.3.1. [^H]-Thymidine incorporation assay 
[^H]-Thymidine incorporation assay was used to estimate DNA synthesis. 
Briefly, l.SxlO"^ cells/well seeded on 96 well-plates were exposed to drugs of different 
dosages for 48 hours. Then, the cells were treated with 1.5 ^iCi ["^H]-thymidine for an 
extra of 24 hours, and the cells were washed twice with ice-cold PBS to terminate 
treatment. [^H]-thymidine labeled DNA was precipitated with 5% ice-cold 
trichloroacetic acid, and cells were solubilized with 0.5 N sodium hydroxide at room 
temperature. The, radioactivity was measured with a liquid scintillation counter 
(Model #: LS3801; Beckman). 
2.2.3.2. MTT assay 
1.5x10^ cells/well seeded on 96 well-plates were exposed to drugs of different 
dosages. After 72 hours of incubation, 30 MTT was added to each well and further 
incubated for 2 hours. Then, the medium was removed by suction and 100 \i\ DMSO 
was added. The plate was shaken on a horizontal shaker to solubilize the dye within 
cells. The absorbance was detected at wavelength 540 nm by a microplate reader 
(Model #: 3550; Bio-rad). 
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2.2.3.3. Data analysis 
The cytokine or drug induced astrocyte proliferation was measured by the 
increase in the amount of [^H]-thymidine incorporated and MTT fonnazan formed 
and expressed as % stimulation. All results were expressed as the arithmetic mean 土 
standard error of quadruplicate determinations. The data shown were representatives 
of at least 3 similar experiments. The Student's "t" test was used to determine the 
confidence limits in group comparison. Normally, p< 0.05 was regarded as 
significantly different. 
2.2.4. Determination of RNA expression by RT-PCR analysis 
In this study, the procedures as described by Lung et al (2001) were followed. 
2.2.4.1. RNA extraction 
5x10^ cells/ml were seeded in 100 mm petri dishes until 90% confluent, 
treated with drugs for various time periods as described in the text, and treatment was 
terminated by placing the dish on ice. The medium was removed and cells were 
washed twice with 10 ml ice-cold PBS. This was followed by the addition of 2 ml 
TRIzol reagent and incubated for 5 minutes at room temperature to lyse the cells 
according to the protocol provided by Invitrogen, Hong Kong. RNA samples were 
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dissolved in nuclease-free water and stored at -20°C until use. 
2.2.4.2. Spectrophotometric quantitation of RNA 
The amount and purity of the isolated nucleic acid were estimated 
spectrophotometrically. An absorbance at 260 nm of 1 is equivalent to approximately 
40 )Lig/ml of RNA. The purity of nucleic acid was determined by the ratio between the 
absorbance at 260 nm and 280 nm, and only preparations of nucleic acid, which had 
OD260/OD280 value between 1.7 and 2.0 were used for RT-PCR studies. A pure RNA 
preparation should have an OD260/ OD280 value of 2.0. 
2.2.4.3. RNA gel electrophoresis 
RNA was separated by 1% agarose gel, which was prepared by dissolving 1% 
agarose (w/v) in TBE buffer. The RNA samples were heated to 65°C for 20 minutes 
prior to gel electrophoresis. The gel was run at 125 V in 0.5X TBE buffer for 30 
minutes and stained with 1 )Lig/ml ethidium bromide solution and photographed under 
UV fluorescence to detect the RNA bands. 
2.2.4.4. Reverse transcription-polymerase chain reaction (RT-PCR) 
Usually, one )ig of total RNA was reverse-transcribed in a 20 |al-reaction 
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mixture containing 20 U of AMV reverse transcriptase, 5 mM MgCb, 1 mM of each 
dNTP, 40 U of RNase inhibitor, 3.2 [ig random primer p(dN)6, 10 mM Tris-HCl, pH 
8.3 and 50 mM KCl. The mixture was incubated at 25°C for 10 min, then 42�C for 60 
min, heated to 99�C for 5 min and cooled to 4 � C for 10 min. The RT samples were 
used immediately or stored at -20°C. 
PCR was performed in a total volume of 25 consisting of 0.625 to 0.5 |al of 
RT sample (equivalent to 31.25-125 i^g of total RNA), 0.625 U of Taq DNA 
polymerase, 1.5 mM MgCh, 0.2 mM of each dNTP, 0.2 |aM of both sense and 
antisense oligonucleotides, 10 mM Tris-HCl, pH 8.3 and 50 mM KCl in a PCR 
machine (GeneAmp PCR system 9700, PerkinElmer, U.S.A.). The PCR conditions 
were 94�C for 5 min, then 25 to 35 cycles of 94�C for 0.5 min, 57 to 61�C for 0.5 min 
to 1 min 15 s, 72®C for 1 min to 1 min 15 s, followed by final extension of 5 min at 
I T C . The sequences of the PCR primers used in this study were summarized in Table 
2.1. The PCR products were used immediately or stored at -20°C. 
2.2.4.5. Separation of PCR products by agarose gel electrophoresis 
A 5 ).il-aliquot of PCR products was loaded with 6X loading buffer and 
separated on a 2% (w/v) agarose gel. The gel was run in 0.5X TBE buffer at 100 V for 
one hour, stained with 1 |ag/ml ethidium bromide solution and photographed under 
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UV fluorescence using a gel documentation system (Bio-rad). 
2.2.4.6. Quantification of band density 
The density of the PCR product was semi-quantified by densitometry using 
ImageQuant (Microsoft) by Molecular Dynamics. The density of the target gene was 
first normalized by dividing its density by that of the P-actin gene in the same sample, 
then the normalized value of the treated sample was divided by the normalized value 
of the corresponding control in the same set of treatment to obtain the relative density 
value. The higher densitometry value suggested higher gene expression. 
2.2.5. Determination of protein expression by Western blotting 
2.2.5.1. Total protein extraction 
5x10^ cells/ml seeded in 100 mm petri dish were treated with various dosages 
of drugs for various times and treatment was terminated by placing the dish on ice. 
Total protein was extracted followed the protocol from Santa Cruz, U.S.A. with slight 
modifications. Briefly, medium was discarded and cells were washed with ice-cold 
PBS twice. 0.8 ml RIPA buffer was added and incubated on ice for 15 minutes. Then, 
cell lysate was collected and incubated at 4°C for 45 minutes with 10 of 10 mg/ml 
PMSF added. The cell lysate was centrifuged at 10000 x g for 15 min and the 
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supernatant was the total protein. The protein contents were determined by Bradford 
method using bovine serum albumin as the standard. 
2.2.5.2. Western blot analysis 
For this study, 15 to 25 \xg protein sample was electrophoresed in 7.5 to 15% 
polyacrylamide gel. The gel was run at 125 V. After electrophoresis, the protein bands 
were transferred onto a polyvinylidene difluoride (PVDF) membrane (Amersham, 
UK). The non-specific binding sites were blocked by incubating the membrane in 
blocking buffer overnight. The membrane was rinsed twice in washing buffer. The 
membrane was incubated in diluted (1:1000 to 1:5000 in PBS-T) primary antibody for 
1 hour at room temperature. The membrane was washed sufficiently with several 
changes of fresh washing buffer. The membrane was incubated in diluted (1:1000 to 
1:5000 in PBS-T) horse radish peroxidase (HRP)-labeled secondary antibody for 1 
hour at room temperature. Then, the membrane was washed as before. The membrane 
was incubated with ECL+Plus detection reagent for 5 minutes at room temperature. 
The final volume of detection reagent was 0.1 ml/cm^. The PVDF membrane was 
exposed to a hyperfilm (Amersham, U.K.) and the intensity of each band was 
semi-quantified using ImageQuant (Microsoft). 
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CHAPTER 3. RESULTS 
3.1. Effects of pro-inflammatory cytokines on astrocyte proliferation 
Since astrocytes proliferation is one of the major steps in astrogliosis and glial 
scarring, and it has been reported that cytokines play important roles in the 
pathological events of many neurological diseases (Arvin et al., 1996; Woodroofe, 
1995; Rothwell et al., 1993), it is of importance to know whether astrocyte 
proliferation and cytokines are related. In fact, some cytokines have been shown to 
induce astrogliosis and GFAP overexpression (Zhang et al., 1999; Balasingam et al., 
1994; Selmaj et qi, 1990). However, the cytokines specific to astrocyte proliferation 
have not yet been determined. In this study, we examined the effects of five cytokines, 
including TNF-a, IL- la , IL-1 (3, IL-6 and IFN-y, on the proliferation of cultured rat 
astrocytes, in order to elucidate their roles in astrogliosis. Cells were treated with 
different concentrations of cytokines and proliferation was determined according to 
the methods described in Section 2.2.3. The proliferation was monitored with the 
amount of MTT formazan formed in the MTT assay or measured the amount of 
[^H]-thymidine incorporated. 
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3.1.1. Effects of TNF-a on astrocyte proliferation 
Astrocytes treated with 10-1000 U/ml TNF-a showed a dose-dependent 
increase in MTT formazan formation (Fig. 1). TNF-a, at lower concentrations 
(10-100 U/ml), was more effective in stimulating the proliferation of astrocytes and 
the optimal stimulation of 33.5% was obtained with 10 U/ml TNF-a. The stimulatory 
effect declined at 500 U/ml of TNF-a and no significant stimulation was obtained 
with 1000 U/ml. In addition, TNF-a increased the DNA synthesis of astrocytes in a 
dose-dependent manner (Fig. 2). TNF-a, at lower concentrations (1-100 U/ml), had a 
higher stimulation on the cell proliferation and the maximum stimulation of 60.3% 
was obtained with 100 U/ml, but slight inhibition was seen at 1000 U/ml. 
« 
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Fig. 1 Effects of TNF-a on astrocyte proliferation. Astrocytes were treated with 10 
to 1000 U/ml of TNF-a for 72 hours, and then MTT assay was performed as 
described in Section 2.2. Results were expressed as percentage of stimulation and 
each point represents the mean 土 standard error of four replicate wells of three 
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Fig. 2 Effects of TNF-a on astrocyte DNA synthesis. Astrocytes were treated with 
1 to 1000 U/ml TNF-a for 48 hours, and [^H]-thymidine incorporation was 
determined as described in Section 2.2. Results were expressed as percentage of 
stimulation and each point represents the mean 士 standard error of four replicate 
wells of three separate experiments. *P<0.05, significantly different from control 
using Student's t-test. 
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3.1.2. Effects of TNF-Rl and -R2 antibodies on astrocyte proliferation 
Two TNF receptors, TNF-Rl and -R2, have been identified in astrocytes; 
however, the functions of each subtype are still controversial (Tartaglia and Goeddel, 
1992). Recently, antibodies against TNF-Rl and -R2 have been used as receptor 
agonists to study TNF activities (Grell et al., 1998; Tartaglia et al., 1991). Hence, we 
used selective antibodies to examine the role of each subtype in the TNF-a-induced 
proliferation of astrocytes. It was observed that TNF-R2 antibody at 500 ng/ml 
showed 39.5% stimulation on astrocyte proliferation and the stimulation declined as 
its concentration increased (Fig. 3). In contrast, TNF-Rl antibody, at all 
concentrations tested, inhibited the proliferation of astrocytes and the inhibition varied 
with the antibody concentration added (Fig. 3). 
The action of TNF-R2 antibody was confirmed by measuring its effect on 
DNA synthesis. TNF-R2 antibody at 500 ng/ml increased the DNA synthesis of 
astrocytes (Fig. 4) and the highest stimulation was 43.9%. However, at higher 
antibody concentrations (2500-5000 ng/ml), reduced the DNA synthesis of astrocytes. 
It seems that activating the TNF-R2 with low concentrations of its antibody can 
stimulate astrocyte proliferation. 
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Fig. 3 Effects of TNFR antibodies on astrocyte proliferation. Astrocytes were 
treated with 50 to 5000 ng/ml TNF-Rl or TNF-R2 antibody for 72 hours. Then, 
MTT assay was performed as described in Section 2.2. Results were expressed as 
percentage of stimulation and each point represents the mean 土 standard error of four 
replicate wells of three separate experiments. *P<0.05, significantly different from 
control using Student's t-test. 
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Fig. 4 Effects of TNF-R2 antibody on astrocyte DNA synthesis. Astrocytes were 
treated with 50 to 5000 ng/ml TNF-R2 antibody for 48 hours and [^H]-thymidine 
incorporation was determined as described in Section 2.2. Results were expressed as 
percentage of stimulation and each point represents the mean 士 standard error of four 
replicate wells of three separate experiments. *P<0.05, significantly different from 
control using Student's t-test. 
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3.1.3. Effects of other cytokines on astrocyte proliferation 
As it has been reported that cytokines other than TNF-a also promote 
astrogliosis (Balasingam et al., 1994; Selmaj et al., 1990), the effects of other 
pro-inflammatory cytokines on the proliferation of astrocytes were examined to see if 
cytokine specificity existed. 
We found that IL-1 a , IL-ip and IFN-y at 10-100 ng/ml significantly 
stimulated the cleavage of MTT, but only weak stimulation occurred at 0.1-1 ng/ml 
(Fig. 5). In contrast, IL-6 only showed 15% stimulation on the proliferation of 
astrocytes even at a much higher concentration (100 ng/ml) (Fig. 5). 
The actions of cytokines on astrocyte were confirmed by [^H]-thymidine 
incorporation assay. IL-1 a and IL-ip at 1-100 ng/ml significantly increased the DNA 
synthesis of astrocytes and their optimal stimulations were 21.5 and 26.7% at 100 and 
10 ng/ml, respectively (Fig. 6). IL-1 (3 was more effective than IL-1 a , as the 
proliferation induced by IL-ip, at all concentrations tested, was greater than that of 
IL-1 a . On the other hand, IL-6 and IFN-y did not show significant stimulation on 
DNA synthesis even at high concentrations (Fig. 6); thus they may not play major 
roles in the proliferation of astrocytes. Altogether, it seems that different cytokines 
showed different effects on astrocyte proliferation. 
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Fig. 5 Effects of IL-la , IL-1 (3, IL-6 and IFN-y on astrocyte proliferation. 
Astrocytes were treated with 0.1 to 100 ng/ml IL-la , IL-ip, IL-6 or IFN-y for 72 
hours and MTT assay was performed as described in Section 2.2. Results were 
expressed as percentage of stimulation and each point represents the mean 土 
standard error of four replicate wells of three separate experiments. *P<0.05, 
significantly different from control using Student's t-test. 
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Fig. 6 Effects of IL- la , IL-ip, IL-6 and IFN-y on astrocyte DNA synthesis. 
Astrocytes were cultured with 0.1 to 100 ng/ml IL-la , IL-1 (3, IL-6 or IFN-y for 48 
hours and [^H]-thymidine incorporation was determined as described in Section 
2.2. Results were expressed as percentage of stimulation and each point represents 
the mean 土 standard error of four replicate wells of three separate experiments. 
*P<0.05, significantly different from control using Student's t-test. 
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3.1.4. Comparisons of the effects of cytokines on astrocyte proliferation 
In this study, the actions of five cytokines (i.e. TNF-a, IL- la , IL-1 (3, IL-6 and 
IFN-Y) on DNA synthesis in astrocytes were compared. We found that similar amount 
of the cytokines had diverse effects on astrocyte proliferation (Fig. 7). Among the 
cytokines, astrocytes were more sensitive to TNF-a and the maximum stimulation of 
60.3% on the DNA synthesis was observed, whereas IL-6 and IFN-y did not show 
significant effect at this concentration and IL- la and IL-1 (3 only had 18% and 26.7%, 
respectively. This indicates that the proliferative effect exerted by these cytokines on 
astrocytes is specific. 
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Fig. 7 Comparisons of the effects of different cytokines on astrocyte DNA 
synthesis. Astrocytes were treated with 1 ng/ml IFN-y, IL-6, IL- la and IL-lp or 100 
U/ml TNF-a for 48 hours, and then [^H]-thymidine incorporation was determined as 
described in Section 2.2. Results were expressed as percentage of stimulation and 
each point represents the mean 土 standard error of four replicate wells of three 
separate experiments. '^P<0.05, significantly different from control using Student's 
t-test. 
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3.2. Effects of P-agonist and -antagonist on astrocyte proliferation 
Besides cytokines, recent in vivo studies have reported that (3-adrenergic 
mechanism regulated astrogliosis and astrocyte proliferation (Hodges-Savola et al., 
1996; Sutin and Griffith, 1993), it is of interest to examine whether TNF-a and 
p-adrenergic mechanism are closely related in astrocyte proliferation. In our 
laboratory, we previously found that cultured rat astrocytes expressed both Pi- and 
p2-AR (Lung, 1999). In this study, we used isoproterenol and propranolol to study the 
effect of P-AR on astrocyte proliferation. 
It was seen that isoproterenol inhibited the DNA synthesis of astrocytes for 
about 50% (Fig. 8). In addition, isoproterenol dose-dependently reduced the number 
of astrocytes (Fig. 9). When treating astrocytes with TNF-a and isoproterenol together, 
the inhibition exerted by isoproterenol on the proliferation was partially relieved. In 
other words, the proliferative effect of TNF-a was hindered by p-adrenergic 
activation. As isoproterenol is a potent adenylate cyclase activator (Rosenberg and Li, 
1995), we examined the effect of dbcAMP on the proliferation of astrocytes. Results 
of Fig. 10 showed that dbcAMP had a strong reduction in number of astrocytes. On 
the other hand, propranolol did not significantly affect the TNF-a-induced 
proliferation (Fig. 11). So, the TNF-a-induced proliferation is not directly regulated 
by P-adrenergic mechanism. 
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Fig. 8 Effects of isoproterenol on astrocyte DNA synthesis. Astrocytes were 
cultured with 25 to 5000 nM isoproterenol for 48 hours and [^H]-thymidine 
incorporation was determined as described in Section 2.2. Results were expressed 
as percentage of stimulation and each point represents the mean 士 standard error of 
four replicate wells of three separate experiments. *P<0.05, significantly different 
from control using Student's t-test. 
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Fig. 9 Effects of isoproterenol on astrocyte proliferation. Astrocytes were cultured 
with 25 to 5000 nM isoproterenol in the absence or presence of 100 U/ml TNF-a for 
72 hours and MTT assay was performed as described in Section 2.2. Results were 
expressed as percentage of stimulation and each point represents the mean 土 
standard error of four replicate wells of three separate experiments. **P<0.05, 
significantly different .from control using Student's t-test. *P<0.05, significantly 
different from TNF-a only. 
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Fig. 10 Effects of dbcAMP on astrocyte proliferation. Astrocytes were cultured 
with 5 to 1000 |JM dbcAMP for 72 hours and MTT assay was performed as 
described in Section 2.2. Results were expressed as percentage of stimulation and 
each point represents the mean 士 standard error of four replicate wells of three 
separate experiments. *P<0.05, significantly different from control using Student's 
t-test. “ ‘ 
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Fig. 11 Effects of propranolol on astrocyte proliferation. Astrocytes were cultured 
with 50 to 10000 nM propranolol in the absence or presence of 100 U/ml TNF-a for 
72 hours and MTT assay was performed as described in Section 2.2. Results were 
expressed as percentage of stimulation and each point represents the mean 土 
standard error of four replicate wells of three separate experiments. *P<0.05, 
significantly different from control using Student's t-test. 
I ‘ 
• 5 9 
3.3. Effects of TNF-a on the expression of TNFRs and endogenous 
TNF-a in astrocytes 
Recently, it has been reported that TNF-a is important in control of cell 
apoptosis and proliferation, and it is proposed that the events triggered by TNF-a 
depend on the relative densities of the TNFR subtypes on cell surface (MacEwan, 
2002). Our previous results showed that TNF-R2, but not TNF-Rl, was responsible 
for the proliferative action on cultured astrocytes (Figs. 3 & 4). So, it is of our interest 
to know whether this cytokine affects the expression of TNFR subtypes. Besides, we 
characterized the TNF-a postreceptor signal transduction mechanism leading to the 
expression of these genes. RT-PCR was used to detect mRNA expression and western 
blot analysis was used to measure protein expression as described in Sections 2.2.4 
and 2.2.5. 
3.3.1. Effects of TNF-a on the expression of TNF-Rl and -R2 in astrocytes 
3.3.1.1. Effects of TNF-a on the expression of TNF-Rl and -R2 mRNA 
A time-course experiment on the effect of TNF-a on TNF-Rl and -R2 genes 
expression was performed. Fig. 12 showed the mRNA levels of TNF-Rl and -R2 after 
exposed to 500 U/ml TNF-a for 5 minutes to 48 hours. This concentration of TNF-a 
(500 U/ml) was required to observe a response at as early as 5 minutes, although 100 
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u/ml TNF-a had more prominent proliferation stimulatory effect on astrocytes (Fig. 
2). The p-actin mRNA was used as the internal standard for equal loading in this and 
other similar studies. 
For TNF-R2 mRNA level, it was increased at as early as 5 minutes, remained 
higher than control even for 48 hours, and the optimal induction (of about 3-folds) 
was observed at 2 hours (Fig. 12). However, the mRNA levels ofTNF-Rl and p-actin, 
as monitored with various PGR cycles, were relatively constant throughout (Fig. 12). 
This indicates that TNF-a selectively induces the TNF-R2 gene expression in 
astrocytes. Additionally, the mRNA level of TNF-Rl was higher than that of TNF-R2, 
suggesting that TNF-Rl is the major subtype in astrocytes as suggested by Dopp et al 
(1997). 
The dose effects of TNF-a on TNF-Rl and -R2 mRNA levels were also 
examined. Fig. 13 showed the mRNA levels of both subtypes exposed to 10-1000 
U/ml TNF-a for 2 hours, the time required for maximal induction. For TNF-R2, its 
expression was enhanced in a dose-dependent manner and the optimal stimulation 
was obtained with 1000 U/ml TNF-a. TNF-Rl and P-actin mRNA levels did not 
significantly change (Fig. 13). It seems that TNF-a induces astrocyte proliferation via 
upregulation of the expression of TNF-R2, the subtype related to cell proliferation. 
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3.3.1.2. TNFR subtypes involved in the TNF-a-induced TNF-R2 mRNA expression 
In our laboratory, we found that antibodies against TNF-Rl and -R2 could 
block the effect of TNF-a on genes expression when they were added two hours 
before TNF-a exposure (To, 1999). So, we examined the effects of TNF-Rl and -R2 
antibodies on the TNF-a-induced TNF-R2 expression to know which subtype was 
involved. Astrocytes were exposed to 50-5000 ng/ml TNFR antibody for 2 hours 
before the addition of 500 U/ml TNF-a for another 2 hours of incubation. 
Blocking the TNF-Rl enhanced the mRNA expression of TNF-R2 (Fig. 14a), 
while blocking the TNF-R2 not only abolished the TNF-R2 gene expression induced 
by TNF-a and in fact the expression was reduced (Fig. 15a). However, treating with 
either antibody alone did not significantly alter the TNF-R2 mRNA level (Figs. 14b & 
15b). Altogether, these data suggest that the TNF-a-induced TNF-R2 gene expression 
is mediated through TNF-R2. 
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Time treatment of 500 U/ml TNF-a (min) 
c 5 10 20 30 60 120 240 1440 2880 
TNF-Rl 卿 i �‘ ' 1 - 3 2 2 bp 
1 1.05 1.06 1.16 1.22 丨.32 1.29 1.26 1.3 1.16 
1 1.26 1.41 1.78 2.42 2.88 3.64 3.51 2.67 1.33 
Fig. 12 Effects of TNF-a on the levels of TNF-Rl, -R2 and P-actin mRNA in 
astrocytes. Cells were treated with 500 U/ml TNF-a for 5 minutes to 48 hours and 
total RNA was extracted and followed by RT-PCR as described in Section 2.2. Data 
presented are representatives of three separate experiments with similar results. 
J ‘ 
. 6 3 
Dose treatment of TNF-a (U/ml) 
C 10 100 500 1000 
TNF-Rl • �� � - 322 bp 
1 1.03 1.07 1.12 0.94 
TNF-R2 — 256 bp 
1 0.72 2.66 2.62 3.17 
P-actm f m m ^ ^ K m " _ 201 bp 
Fig. 13 Effects of TNF-a on the levels of TNF-Rl, TNF-R2 and P-actin mRNA in 
astrocytes. Cells were treated with 10 to 1000 U/ml TNF-a for 2 hours and total RNA 
was extracted and followed by RT-PCR as described in Section 2.2. Data presented 
are representatives of three separate experiments with similar results. 
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(a) 
TNF-Rl antibody (ng/ml) + TNF-a 
I ‘ . 
C TNF-a 5000 2500 500 50 
1 1.33 1.67 2.12 1.67 1.56 
P-actin - 201 bp 
(b) 
TNF-Rl antibody (ng/ml) 
C 5000 2500 500 50 
TNF-R2 
1 1.16 1.03 1.01 1.29 
Fig. 14 Effects of TNF-Rl antibody on the levels of TNF-R2 and P-actin mRNA 
induced by TNF-a in astrocytes. Cells were treated with (a) 50 to 5000 ng/ml TNF-Rl 
”antibody for 2 hours before exposure to 500 U/ml TNF-a for another 2 hours or (b) 50 
to 5000 ng/ml TNF-Rl antibody alone for 2 hours. Then, total RNA was extracted and 
followed by RT-PCR as described in Section 2.2. Data presented are representatives of 
three separate experiments with similar results. 
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(a) 
TNF-R2 antibody (ng/ml) + TNF-a 
I 1 
C TNF-a 5000 2500 500 50 
TNF-R2 U j j i m j j m j j ^ i ' ^ ^ ^ j ^ g j m g j l � 256 bp 
1 1.79 0.8 0.85 0.74 0.75 
(b) 
TNF-R2 antibody (ng/ml) 
C 5000 2500 500 50 
— 1 1 1.24 1.27 1.31 
p-actin i * * " " " " ' " ' ' y " " 國 爭 … 1 ， … h 
” HHMMIilHiflliHHMMMflklHglHiliiAi•急，^hHMwa^ - 201 bp 
Fig. 15 Effects of TNF-R2 antibody on the levels of TNF-R2 and P-actin mRNA 
induced by TNF-a in astrocytes. Cells were treated with (a) 50 to 5000 ng/ml TNF-R2 
antibody for 2 hours before exposure to 500 U/ml TNF-a for another 2 hours or (b) 50 
to 5000 ng/ml TNF-R2 antibody alone for 2 hours. Then, total RNA was extracted and 
followed by RT-PCR as described in Section 2.2. Data presented are representatives of 
three separate experiments with similar results. 
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Signaling pathways of the TNF-a-induced TNF-R2 mRNA expression 
The above studies indicate that TNF-R2 was responsible for the action of 
TNF-a on TNF-R2 gene expression. To further the study, the postreceptor signal 
transduction, particularly the PKA and PKC pathways, were examined. 
First, astrocytes were exposed to 0.05-5 ng/ml PMA, a PKC activator. It was 
found that 0.05-0.5 ng/ml PMA could stimulate the expression of TNF-R2 gene, but 
the TNF-R2 mRNA level was reduced at 5 ng/ml PMA (Fig. 16a). This maybe due to 
the nonspecific action or downregulation of TNF-R2 gene at high doses of PMA 
(Holtmann and Wallach, 1987). To confirm the role of PKC, 10-1000 nM Ro-31, a 
selective PKC inhibitor, were added to cells before TNF-a induction. Two hours have 
been found to be sufficient to block PKC action in C6 glioma cells (Tsang et al., 
1997). Ro-31 alone did not significantly affect the TNF-R2 gene expression (Fig. 
17b). However, Ro-31 dose-dependently affected the TNF-a-induced TNF-R2 mRNA 
level and the inhibition was greater than 50% with 10-100 nM (Fig. 17a). Thus, PKC 
pathway is likely to be involved in the TNF-a-induced TNF-R2 expression. 
- T h e n , effect of 0.5-500 \iM dbcAMP, a PKA activator, on TNF-R2 gene 
expression was studied. dbcAMP, at all concentrations tested, showed strong inducing 
effect on the TNF-R2 mRNA level and the stimulation was greater than 2-folds (Fig. 
16b). To ascertain the involvement of PKA in the action of TNF-a, astrocytes were 
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incubated with or without 0.05-5 |iM H89, a selective PKA inhibitor, alone for 2 
hours then in the presence of 500 U/ml TNF-a for an extra 2 hours. H89 alone 
slightly increased the TNF-R2 mRNA level (Fig. 18b) and H89 at low concentrations 
of 0.05-2.5 laM did not reduce the TNF-a-induced TNF-R2 mRNA expression (Fig. 
18a). At higher concentration (5 |aM), slight inhibition was observed and this maybe 
due to the nonspecific effect as the Kj of H89 for PKA has been reported to be less 
than 50 nM (Ho et al, 1999). Although PKA could upregulate the TNF-R2 gene 
expression, it is not essential for the TNF-a-induced TNF-R2 gene expression. 
3.3.1.4. Effects of TNF-a on the expression of TNF-Rl and -R2 protein 
Upon exposure to TNF-a, the level of TNF-R2 protein was enhanced, which 
peaked at 6 hours and this induction was still observed after 72 hours (Fig. 19). The 
level of TNF-R2 in the control was very low, which agreed with the low level of 
TNF-R2 mRNA (Fig. 12). The level of TNF-Rl protein was already high in the 
control and the level was also induced, but the degree was less (Fig. 19). These 
findings confirmed that TNF-a selectively induced the expression of TNF-R2 both 
at mRNA and protein levels. Additionally, the level of TNF-R2 protein was lower 
than that of TNF-Rl in unstimulated astrocytes. This finding showed that TNF-Rl is 
the predominant subtype in astrocytes (Dopp et al., 1997). 
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(a) 
PMA (ng/ml) 
C 5 1 0.5 0.05 
爾 1 ^ ， � ” 1 • ： 碌 , _ 256 bp 
1 0.75 1.1 1.75 1.91 
�� 〜 鱅 _ 1 — ^ � , _" I I I 一 201 bp 
(b) 
dbcAMP (i^M) 
C 500 50 5 0.5 
TNF-Rl 鄉 警 � ^ - 2 5 6 bp 
k'/mf^  等‘、-广梦 ： . 广〜广' 、二 、 
• 1 2.76 3.05 2.65 2.01 
P aetin ！―!!—!!!^, "Ai 111i111_ im i i咖___ii13lt_i_i i i i i3i - 201 bp 
Fig. 16 Effects of PMA and dbcAMP on the levels of TNF-R2 and P-actin mRNA in 
astrocytes. Astrocytes were treated with (a) 0.05 to 5 ng/ml PMA or (b) 0.5 to 500 |aM 
“for 2 hours and total RNA was extracted and followed by RT-PCR as described in 
Section 2.2. Data presented are representatives of three separate experiments with 
similar results. 
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Ro-31 (nM) +TNF-a 
I ‘ 1 
C TNF-a 1000 500 100 10 
TNF-R2 、 二 ， 、 答 . 二 - 2 5 6 bp 
1 2.56 1.76 1.49 1.1 0.77 
- 201 bp 
(b) 
Ro-31 (nM) 
C 1000 500 100 10 
TNF-R2 ��� 
1 1.02 1.24 1.13 1.26 
p-actm � , ^ • 饭 . 各 lifcIIIIiiiiiiHI . ^ J m m ^ i ^ m a ^ _ 201 bp 
Fig. 17 Effects of Ro-31 on the levels of TNF-R2 and P-actin mRNA induced by 
TNF-a in astrocytes. Astrocytes were treated with (a) 10 to 1000 nM Ro-31 for 2 
..hours before exposure to 500 U/ml TNF-a for another 2 hours or (b) 10 to 1000 nM 
Ro-31 alone for 2 hours. Then, total RNA was extracted and followed by RT-PCR as 
described in Section 2.2. Data presented are representatives of three separate 
experiments with similar results. 
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(a) 
H89 (|iM) + TNF-a 
I ‘ 1 
C TNF-a 5 2.5 0.5 0.05 
TNF-R2 镲 • ^ 麵 • — 256 bp 
1 1.59 1.23 1.51 1.66 1.5 
P-actin ； ^ � ^ ” • 罗 待 繁 ‘ 、 _ 201 bp 
(b) 
H 8 9 ( I IM) 
C 5 2.5 0.5 0.05 
TNF-R2 i ^ ^ ^ ^ m g g m m g j - 2 5 5 bp 
• 丨 1.21 1.33 1.36 1.29 
Fig. 18 Effects of H89 on the levels of TNF-R2 and p-actin mRNA induced by 
TNF-a in astrocytes. Astrocytes were treated with (a) 0.05 to 5 |LIM H89 for 2 hours 
before exposure to 500 U/ml TNF-a for another 2 hours or (b) 0.05 to 5 |iM H89 
alone for 2 hours. Then, total RNA was extracted and followed by RT-PCR as 
described in Section 2.2. Data presented are representatives of three separate 
experiments with similar results. 
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Time treatment of 500 U/ml TNF-a (min) 
C 45 90 180 360 1440 2880 4320 
TNF-Rl - 55 kda 
1 1.12 0.97 1.37 1.28 1.31 1.37 1.38 
TNF-R2 — 75 kda 
1 1.12 0.79 2.38 2.6 2.34 2.21 2.14 
Fig. 19 Effects of TNF-a on the levels of TNF-Rl and -R2 protein in astrocytes. 
Astrocytes were treated with 500 U/ml TNF-a for 45 minutes to 72 hours and total 
protein was extracted and followed by Western blot analysis as described in Section 
2.2. Data presented are representatives of three separate experiments with similar 
results. 
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3.3.2. Effects of TNF-a on the expression of endogenous TNF-a in astrocytes 
3.3.2.1. Effects of TNF-a on the expression of TNF-a mRNA 
Fig. 20 showed that 500 U/ml TNF-a induced the mRNA expression of the 
endogenous TNF-a in astrocytes in a time-dependent manner. The mRNA level of 
TNF-a was enhanced after 20 minutes and the maximum induction (of 20-folds) was 
observed at 2-4 hours. Although the induction declined, it remained higher than that 
of the control even after 48 hours. This indicates that TNF-a regulates positively 
itself in cultured rat astrocytes. In additional to the temporal effect, dose effect of 
TNF-a on the endogenous TNF-a gene was examined. TNF-a 
concentration-dependently stimulated the TNF-a gene expression and the optimal 
stimulations were obtained with 500 and 1000 U/ml TNF-a (Fig. 21). These 
observations are in agreement with previous report that astrocytes can produce 
TNF-a upon stimulation (Benveniste and Benos, 1995). 
3.3.2.2. TNFR subtypes involved in the TNF-a-induced TNF-a mRNA expression 
Pre-treatment with TNF-Rl antibody clearly enhanced the TNF-a-induced 
TNF-a mRNA expression, especially at 2500 and 5000 ng/ml (Fig. 22a). On the other 
hand, the induction of TNF-a gene was almost completely blocked by TNF-R2 
antibody, at all concentrations tested (Fig. 23a). These observations were not due to 
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the antibodies effects because treatment with either antibody alone was not effective 
to induce the TNF-a gene expression (Figs. 22b & 23b). The above finding indicates 
that the TNF-a-induced TNF-a gene expression is mediated via TNF-R2. 
3-3.2.3. Signaling pathways of the TNF-a-induced TNF-a mRNA expression 
The temporal effect of 0.5 ng/ml PMA on TNF-a mRNA expression was 
studied. Fig. 24 showed that PMA induced the TNF-a mRNA expression in a 
time-dependent manner and the optimal stimulation occurred at 30 minutes, and the 
expression profile was similar to that of 500 U/ml TNF-a (Fig. 20). This suggests that 
PKC was involved in the TNF-a gene expression, which is in agreement with the 
preliminary report of Chung et al (1992). On the other hand, dbcAMP, at all 
concentrations tested, did not induce the TNF-a gene expression (results not shown). 
In order to verify the effects of PMA and dbcAMP, astrocytes were treated 
with various doses of Ro-31 or H89 for 2 hours before exposure to TNF-a for an 
additional 2 hours. Ro-31, a selective PKC inhibitor, alone did not induce the TNF-a 
gene expression (Fig. 25b). However, the TNF-a-induced TNF-a mRNA level was 
apparently reduced by Ro-31, at all concentrations tested (Fig. 25a). Interestingly, 
Ro-31 could not totally inhibit the TNF-a expression, suggesting that other regulatory 
pathways maybe involved in the induction of TNF-a gene. For example, MAPK 
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inhibitors have been used to inhibit the induction of TNF-a gene (Bhat et al, 1998). 
H89 alone did not trigger TNF-a gene expression (Fig. 26b). In addition, reduction of 
the TNF-a-induced TNF-a gene expression did not occur at all H89 concentrations 
tested (Fig. 26a). Altogether, it seems that PKC, but not PKA, is likely to be involved. 
3.3.2.4. Effects of other cytokines on the expression of TNF-a mRNA 
Both IFN-y and IL-6 were ineffective in triggering TNF-a gene expression 
(Fig. 27). On the contrary, both IL-1 a and IL-ip were very potent in inducing the 
TNF-a mRNA expression (Fig. 28). IL-1 a greatly stimulated the TNF-a gene 
expression at higher concentrations (10-100 ng/ml). IL-ip was much more potent 
and about 14-folds increase was observed at 0.1 ng/ml. Interestingly, IL6 and IFN-y, 
which were unable to stimulate astrocyte proliferation (Fig. 6), showed very weak 
induction in TNF-a gene. Thus, the effects of cytokines on endogenous TNF-a 
expression are specific. 
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Time treatment of 500 U/ml TNF-a (min) 
C 5 10 20 30 60 120 240 1440 2880 
1 1.5 1.27 5.54 12.49 19.04 20.89 20.13 12.03 4.73 
p_actin � � - ��� V - 2 0 1 b 
- . » … — ^ . - -
Fig. 20 Effects of TNF-a on the levels of TNF-a and P-actin mRNA in astrocytes. 
Cells were treated with 500 U/ml TNF-a for 5 minutes to 48 hours and total RNA was 
extracted and followed by RT-PCR as described in Section 2.2. Data presented are 
representatives of three separate experiments with similar results. 
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Dose treatment of TNF-a (U/ml) 
C 10 100 500 1000 
資 - … � . - .K；- ‘ - 4 1 1 bp 
TNF-a V � ‘ : '一' . f》、'：jb -
1 6.5 20.5 26.12 30.53 
Bactin Y .. ' 餐 ' W P f l - 201 bp 
Fig. 21 Effects of TNF-a on the levels of TNF-a and P-actin mRNA in astrocytes. 
Cells were treated with 10 to 1000 U/ml TNF-a for 2 hours and total RNA was 
extracted and followed by RT-PCR as described in Section 2.2. Data presented are 
representatives of three separate experiments with similar results. 
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(a) 
TNF-Rl antibody (ng/ml) + TNF-a 
I ‘ 1 
C TNF-a 5000 2500 500 50 
TNF-a i m u f X S I ^ & i B I B I - 411 bp 
1 3.17 5.7 5.34 4.96 2.57 
P-actin - 201 bp 
(b) 
TNF-Rl antibody (ng/ml) 
C 5000 2500 500 50 
TNF-a I I I M ^ I I I I P — i - 411 bp 
1 0.83 1.02 1.07 1.07 
P_actin - 201 bp 
Fig. 22 Effects of TNF-Rl antibody on the levels of TNF-a and P-actin mRNA 
induced by TNF-a in astrocytes. Cells were treated with (a) 50 to 5000 ng/ml TNF-Rl 
“antibody for 2 hours before exposure to 500 U/ml TNF-a for another 2 hours or (b) 50 
to 5000 ng/ml TNF-Rl antibody alone for 2 hours. Then, total RNA was extracted and 
followed by RT-PCR as described in Section 2.2. Data presented are representatives of 
three separate experiments with similar results. 
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(a) 
TNF-R2 antibody (ng/ml) + TNF-a 
I ‘ 1 
C TNF-a 5000 2500 500 50 
TNF-a I 缓 》 ， f T 萬 ’ � … � - 4 1 1 bp 
1 10.36 3.45 4.26 4.35 2.34 
p-actin � — 2U1 bp 
(b) 
TNF-R2 antibody (ng/ml) 
C 5000 2500 500 50 
TNF-a ^^rnm-msfmf：：/ - - - P 
• 1 0.93 0.91 1.12 1.05 
Fig. 23 Effects of TNF-R2 antibody on the levels of TNF-a and P-actin mRNA 
induced by TNF-a in astrocytes. Cells were treated with (a) 50 to 5000 ng/ml TNF-R2 
antibody for 2 hours before exposure to 500 U/ml TNF-a for another 2 hours or (b) 50 
to 5000 ng/ml TNF-R2 antibody alone for 2 hours. Then, total RNA was extracted and 
followed by RT-PCR as described in Section 2.2. Data presented are representatives of 
three separate experiments with similar results. 
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Time treatment of 0.5 ng/ml PMA (min) 
c 5 10 20 30 60 120 1440 
1 1.78 1.78 4.91 4.85 1.69 0.63 0.94 
P-actin ？ ^ 丨 警 ？ 。 二 一 201 hn 
Fig. 24 Effects of PMA on the levels of TNF-a and P-actin mRNA in astrocytes. 
Cells were treated with 0.5 ng/ml PMA for 5 minutes to 24 hours and total RNA was 
extracted and followed by RT-PCR as described in Section 2.2. Data presented are 




Ro-31 (nM) + T N F - a 
C TNF-a 1000 500 100 10 
™ F - a — L ^ U m ' . t ^ ^ ^ 一 411 bp 
1 7.61 2.23 2.98 4.78 2.21 
一 如 t ， 肩 • ， ： ― - 2 0 1 bp 
(b) 
Ro-31 (nM) 
C 1000 500 100 10 
TNF-a • . - - b p 
1 1.04 0.94 0.88 0.86 
P-actin • ' • • • l I p i l i i i i h ^ U J a a ^ W I I ^ ^ ^ M l l 一 201 
Fig. 25 Effects of Ro-31 on the levels of TNF-a and p-actin mRNA induced by 
TNF-a in astrocytes. Cells were treated with (a) 10 to 1000 nM Ro-31 for 2 hours 
.,before exposure to 500 U/ml TNF-a for another 2 hours or (b) 10 to 1000 nM Ro-31 
alone for 2 hours. Then, total RNA was extracted and followed by RT-PCR as 
described in Section 2.2. Data presented are representatives of three separate 




H89 (|iM) + TNF-a 
I ‘ . 
C TNF-a 5 2.5 0.5 0.05 
TNF-a — B B M B g ^ ， : i P ^ ^ g ^ l - 411 bp 
••^^•MH^HHHHB，」.一 m O M m ^ M M I ^ 
1 8.78 8.22 8.9 7.72 9.02 
P-actin 穿 - 2 0 1 bp 
(b) 
H89 ( _ 
C 5 2.5 0.5 0.05 
、 腳 • ^ s f s p f T ^ ^ ^ e - - b p 
1 0.99 1.03 1.12 1.05 
- 2 0 1 bp 
Fig. 26 Effects of H89 on the levels of TNF-a and P-actin mRNA induced by 
TNF-a in astrocytes. Cells were treated with (a) 0.05 to 5 [iM H89 for 2 hours before 
..exposure to 500 U/ml TNF-a for another 2 hours or (b) 0.05 to 5 jiM H89 alone for 2 
hours. Then, total RNA was extracted and followed by RT-PCR as described in 




C 100 10 1 0.1 
TNF-cc i m p ' : 1 - 411 bp 
1 1.12 1.53 1.38 1.17 
P - - r — 丨 - 曙 丨 丨 " I " 
IL-6 (ng/ml) 
C 100 10 1 0.1 
— - a — I I I I , I I I 響 “ 丨 義 ^ ^ ^ ： " ! -411 bp 
1 1.33 1.78 1.67 1.52 
P-actin � . . . … . . . . . . . … … … .置 “ 1 � . 
^ l I M M i B ^ m i l M B B M f f i l — i m i i m i M l M I H M l f — y^j I op 
Fig. 27 Effects of IFN-y and IL-6 on the levels of TNF-a and p-actin mRNA in 
astrocytes. Cells were treated with 0.1 to 100 ng/ml IFN-y or IL-6 for 2 hours. Then, 
total RNA was extracted and followed by RT-PCR as described in Section 2.2. Data 
presented are representatives of three separate experiments with similar results. 
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IL-1 a (ng/ml) 
C 100 10 1 0.1 
™ F - a f C T ‘ - - J B H H - 4 1 1 bp 
1 丨 8.13 4.6 2.04 2.71 
P-actin j^ ^^ l^^ l^ JjU^^ II^ I^Hj^ l^llllll^ l^llljj^ ^^ lll^ i^mi^ l^^ ^^ llll^ l^ lll^  — 201 bp 
IL-1 (3 (ng/ml) 
C 100 10 1 0.1 
TNF a . 411 bp 
1 19.35 18.51 17.6 13.71 
p-actin H ^ J U J J g ^ ^ l J U I ^ ^ ^ ^ J J J J J J J I U g J J U l — 201 bp 
Fig. 28 Effects of IL-1 a and IL-ip on the levels of TNF-a and p-actin mRNA in 
astrocytes. Cells were treated with 0.1 to 100 ng/ml IL-1 a or IL-1 (3 for 2 hours. Then, 
total RNA was extracted and followed by RT-PCR as described in Section 2.2. Data 
presented are representatives of three separate experiments with similar results. 
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3.4. Effects of TNF-a on the expression of Pi- and P2-AR in astrocytes 
Besides TNF-a, (3-adrenergic mechanism has been found to regulate 
astrogliosis and glial scarring (Hodges-Savola et al, 1996; Sutin and Griffith, 1993). 
These findings are detailed by in vivo studies that the density of P-AR was increased 
after brain injury (Mantyh et al., 1995). Therefore, it is likely that TNF-a and P-AR 
are closely related in astrogliosis, so we examined the effects of TNF-a on pi- and 
P2-AR expressions. 
3.4.1. Effects of TNF-a on the expression of (3i- and pi-AR mRNA 
The time-course effects of 500 U/ml TNF-a on the expression of Pi- and 
P2-AR genes were studied. Both Pi- and P2-AR genes were enhanced by TNF-a. The 
maximal induction (of about 3-folds) for pi-AR gene was achieved at 1 hour and 
lasted for 48 hours. For P2-AR mRNA, it was induced after 5 minutes and remained 
higher than that of the control even after 48 hours (Fig. 29). Thus, P2-AR responded to 
the TNF-a induction faster than Pi-AR. Besides the temporal effect, TNF-a also 
increased the Pi- and P2-AR mRNA levels in dose-dependent manners (Fig. 30). In 
agreement with the time-course study, P2-AR was more sensitive to TNF-a as it was 
induced by 10 U/ml TNF-a, but this concentration did not induce the pi-AR gene. 
‘ 85 
Time treatment of 500 U/ml TNF-a (min) 
C 5 10 20 30 60 120 240 1440 2880 
1 1.6 2.13 2.33 2.76 3.9 3.71 2.95 3.78 3.62 
1 2.11 2.65 2.67 2.3 3.13 2.99 2.86 3.02 2.77 
P-actin :'‘’ - • f 广 ‘ - 201 bp 
. 必 •遍fjii idhMMAsBia^�-�、：-- 、 
Fig. 29 Effects of TNF-a on the levels of Pi-, p2-AR and p-actin mRNA in 
astrocytes. Cells were treated with 500 U/ml TNF-a for 5 minutes to 48 hours and 
total RNA was extracted and followed by RT-PCR as described in Section 2.2. Data 
presented are representatives of three separate experiments with similar results. 
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Dose treatment of TNF-a (U/ml) 
C 10 100 500 1000 
Pi-AR i：麵 遷 ‘ ’ 翼 V P 
1 0.92 2.31 2.97 2.88 
n AR 二 勵 � j S ^ : _ ' _ _ _丨 _ 456 bp 
1 2.56 2.57 3.12 3.66 
• If Iif itPIDTir (TlrtHl�rTlllllfinr-i f^y^MMUHHJUBimigailBiaHligilliyillglHIMMMMMMMM^M^^^^^Ma^tM^Ma^^^M^ M^ 
P-actin ' . ^ • m m m ^ m m ^ m r n m a m l ^ ^ ^ m m m m i ^ ^ k ~ 201 bp 
Fig. 30 Effects of TNF-a on the levels of pi-, (32-AR and P-actin mRNA in 
astrocytes. Cells were treated with 10 to 1000 U/ml TNF-a for 2 hours and total 
RNA was extracted and followed by RT-PCR as described in Section 2.2. Data 
presented are representatives of three separate experiments with similar results. 
i " 
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3.4.2. TNFR subtypes involved in the TNF-a-induced Pi- and P2-AR mRNA 
expressions 
Blocking either subtype alone did not affect the basal Pi- and P2-AR mRNA 
levels (Figs. 31b-34b). TNF-Rl antibody at 500-5000 ng/ml strongly enhanced the 
TNF-a-induced pi- and P2-AR mRNA expressions for more than 200% (Figs. 31a & 
33a). On the other hand, blocking the TNF-R2 suppressed the TNF-a-induced P r and 
p2-AR mRNA expressions. For Pi-AR, the suppression was clearly observed at all 
concentrations of TNF-R2 antibody tested (Fig. 32a). For P2-AR, while no clear 
suppression was obtained with 50-500 ng/ml TNF-R2 antibody, the suppression was 
very obvious .at 2500 and 5000 ng/ml (Fig. 34a). Therefore, it seems that the 
TNF-a-induced (3i- and P2-AR genes are regulated throughTNF-R2. 
3.4.3. Signaling pathways of the TNF-a-induced pi- and P2-AR mRNA 
expressions 
A time-course experiment of 0.5 ng/ml PMA on the P r and P2-AR genes was 
performed. While the expression of Pi-AR gene was enhanced after 5 minutes and 
remained high even at 24 hours (Fig. 35), the mRNA level of P2-AR was increased 
only after 20 minutes and leveled off (Fig. 35). The slight decrease observed at 24 
hours maybe to due to the downregulation by stimulating PKC directly (Leavitt et al, 
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2001). Oppositely, dbcAMP, at all concentrations tested, had no effect on pi-AR 
expression, but suppressed that of p2-AR mRNA (Fig. 36). P2-AR gene was more 
susceptible to dbcAMP (Fig. 36). These findings suggest that PKA is not involved in 
mediating the induction of P-AR gene. 
The requirement of PKC in the TNF-a-induced Pi- and P2-AR mRNA 
expressions was further investigated by pre-treating cells with Ro-31 before exposed 
to TNF-a. Basically, Ro-31 alone did not significantly affect the pi- and pz-AR 
mRNA levels (Figs. 37b & 38b). On the other hand, the TNF-a-induced (3, and P2AR 
mRNA expressions were reduced by Ro-31. For pi-AR, its mRNA level was almost 
completely reduced with 100 and 500 nM Ro-31, while incomplete reduction was 
observed at 10 and 1000 nM (Fig. 37a). For P2-AR, Ro-31 only partially suppressed 
the mRNA expression and about 50% inhibition was observed with 500 nM of Ro-31 
(Fig. 38a). Thus, pi-AR gene seems to be more sensitive to Ro-31 inhibition. 
To make sure that induction of the P-ARs mRNA by TNF-a did not require 
PKA, astrocytes were treated with H89 before exposed to TNF-a. Figs. 39b and 40b 
showed that H89 alone did not affect the basal Pi- and P2-AR mRNA levels. Besides, 
the TNF-a-induced Pi- and P2-AR expressions were not appreciably affected by H89 
(Figs. 39a & 40a). Therefore, PKA is unlikely to be involved in the expression of Pi-
and P2-AR genes induced by TNF-a. 
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(a) 
TNF-Rl antibody (ng/ml) + TNF-a 
I ‘ 1 
C TNF-a 5000 2500 500 50 
P _ -- mIII _III -376 bp 
1 1.3 3.12 3.83 3.04 2.78 
P-actin 豐 ： g g i l . H - 201 bp 
(b) 
TNF-Rl antibody (ng/ml) 
C 5000 2500 500 50 
1 0.88 1.03 0.97 1.02 
P-actin ^ ^ g j ； ； ^ 雙 置 : ， j ^ i i i i P 暨 J i P , _ 201 bp 
Fig. 31 Effects of TNF-Rl antibody on the levels of Pi-AR and P-actin mRNA 
induced by TNF-a in astrocytes. Cells were treated with (a) 50 to 5000 ng/ml TNF-Rl 
-ant ibody for 2 hours before exposure to 500 U/ml TNF-a for another 2 hours or (b) 50 
to 5000 ng/ml TNF-Rl antibody alone for 2 hours. Then, total RNA was extracted and 
followed by RT-PCR as described in Section 2.2. Data presented are representatives of 
three separate experiments with similar results. 
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(a) 
TNF-R2 antibody (ng/ml) + TNF-a 
I — — ‘ 1 
C TNF-a 5000 2500 500 50 
Bi~AR — 376 bn 
1 2.14 1.06 1.65 1.39 1.98 
P-actin ^tMi^^^^^^^^^^S^^^Mlikiii^MdBtMWi^HHiiHil "f 
(b) 
TNF-R2 antibody (ng/ml) 
C 5000 2500 500 50 
Pi-AR _ ^^^ bp 
1 1.26 1.19 1.27 1.25 
o • upy聞,11,||丨A，I 丨•^ ijJ^ iijpp^  ” ^Ai^ ^^ ^HRH^HI^ HIIPMi^ ^^ Mi^ jH 
Fig. 32 Effects of TNF-R2 antibody on the levels of Pi-AR and P-actin mRNA 
induced by TNF-a in astrocytes. Cells were treated with (a) 50 to 5000 ng/ml TNF-R2 
antibody for 2 hours before exposure to 500 U/ml TNF-a for another 2 hours or (b) 50 
to 5000 ng/ml TNF-R2 antibody alone for 2 hours. Then, total RNA was extracted and 
followed by RT-PCR as described in Section 2.2. Data presented are representatives of 




TNF-Rl antibody (ng/ml) + TNF-a 
I ‘ 1 
C TNF-a 5000 2500 500 50 
I M I H B B H i l i i l l l l l M M H f t l l l l M i l B i f i l l l H B P P " * "‘丨丨丨" ^ I W i l l l l i l l i i i l i B H m , 
mWHWHBIHWWmMliiMR* sS� '^ Bf 
1 1.4 3.78 3.99 2.45 2.32 
P-actin - 201 bp 
(b) 
TNF-Rl antibody (ng/ml) 
C 5000 2500 500 50 
P 2 - A R - 456 bp 
1 1.21 1.19 1.25 1.18 
P-actin 愿 一 201 bp 
Fig. 33 Effects of TNF-Rl antibody on the levels of P2-AR and P-actin mRNA 
induced by TNF-a in astrocytes. Cells were treated with (a) 50 to 5000 ng/ml TNF-Rl 
antibody for 2 hours before exposure to 500 U/ml TNF-a for another 2 hours or (b) 50 
to 5000 ng/ml TNF-Rl antibody alone for 2 hours. Then, total RNA was extracted and 
followed by RT-PCR as described in Section 2.2. Data presented are representatives of 
three separate experiments with similar results. 
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(a) 
TNF-R2 antibody (ng/ml) + TNF-a 
I ‘ 1 
C TNF-a 5000 2500 500 50 
P2-AR … 一 衡 T 卿 - : � - ！ — 1 —456 bp 
1 3.26 1.96 1.65 3.08 3.36 
(b) 
TNF-R2 antibody (ng/ml) • 
C 5000 2500 500 50 
(32-AR - 456 bp 
1 1.14 1.06 0.89 1.02 
丨 HHpi 丨 ！ y 
Fig. 34 Effects of TNF-R2 antibody on the levels of P2-AR and P-actin mRNA 
induced by TNF-a in astrocytes. Cells were treated with (a) 50 to 5000 ng/ml TNF-R2 
•  antibody for 2 hours before exposure to 500 U/ml TNF-a for another 2 hours or (b) 50 
to 5000 ng/ml TNF-R2 antibody alone for 2 hours. Then, total RNA was extracted and 
followed by RT-PCR as described in Section 2.2. Data presented are representatives of 
three separate experiments with similar results. 
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Time treatment of 0.5 ng/ml PMA (min) 
c 5 10 20 30 60 120 1440 
p j -A R mjJUJSESniSKS^ KSESESI 一 376 bp 
1 1.71 2.1 2.23 2.59 2.08 2.15 1.95 
3MR ..m^^^^aum -''' 
1 1.17 1.16 1.5 1.64 1.7 1.53 1.4 
吁 〒 胃 - bo 
Fig. 35 Effects of PMA on the levels of Pi-, P2-AR and p-actin mRNA in astrocytes. 
Cells were treated with 0.5 ng/ml PMA for 5 minutes to 24 hours and total RNA was 
extracted and followed by RT-PCR as described in Section 2.2. Data presented are 
representatives of three separate experiments with similar results. 
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Dose treatment of dbcAMP (|aM) 
C 500 50 5 0.5 
P,-AR “ ， . ： ’ 诚 ‘ ； 了 ： 驟 — 376 bp 
1 丨.09 0.92 1.13 1.37 
- 4 5 6 bp 
(32-AR 
1 0.86 0.35 0.56 1.24 
P-actin ： 羞 重 … r 二 - 2 0 1 bp 
…'�•�- ‘> ~ . , IillIII 
Fig. 36 Effects of dbcAMP on the levels of Pi-, P2-AR and P-actin mRNA in 
astrocytes. Cells were treated with 0.5 to 500 |aM dbcAMP for 2 hours and total 
RNA was extracted and followed by RT-PCR as described in Section 2.2. Data 
presented are representatives of three separate experiments with similar results. « 
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(a) 
Ro-31 (nM) +TNF-a 
I ‘ 1 
C TNF-a 1000 500 100 10 
…-AR BP^SH^y**—— -376 bp 
1 3.63 2.44 1.21 1.27 2.39 
P-actin … ； ^ ^ _ 201 bD 
(b) 
Ro-31 (nM) 
C 1000 500 100 10 
广ar ICS^^^^^^^SSSSCSt -376 bp 
1 1.02 1.12 1.17 1.31 
R i l i ' i i i| m _ • — — . 
P-actin H n ^ ^ ^ ^ ^ ^ ^ ^ U i J I I i i j g g J U ^ I ^ J I - 201 bp 
Fig. 37 Effects of Ro-31 on the levels of pi-AR and P-actin mRNA induced by 
TNF-a in astrocytes. Cells were treated with (a) 10-1000 nM Ro-31 for 2 hours 
before exposure to 500 U/ml TNF-a for another 2 hours or (b) 10-1000 nM Ro-31 
alone for 2 hours. Then, total RNA was extracted and followed by RT-PCR as 
described in Section 2.2. Data presented are representatives of three separate 
experiments with similar results. 
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(a) 
Ro-31 (nM) +TNF-a 
I ‘ 1 
C TNF-a 1000 500 100 10 
1 3.36 1.92 1.65 1.86 1.65 
P-actin 饕 - 201 h 
(b) 
Ro-31 (nM) 
C 1000 500 100 10 
P2-AR 靈 • I - 456 bp 
1 1 1.07 0.93 1.12 
P-actin — 201 bp 
Fig. 38 Effects of Ro-31 on the levels of p2-AR and P-actin mRNA induced by 
TNF-a in astrocytes. Cells were treated with (a) 10-1000 nM Ro-31 for 2 hours 
. .before exposure to 500 U/ml TNF-a for another 2 hours or (b) 10-1000 nM Ro-31 
alone for 2 hours. Then, total RNA was extracted and followed by RT-PCR as 
described in Section 2.2. Data presented are representatives of three separate 
experiments with similar results. 
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(a) 
H89 ( _ + TNF-a 
I ‘ , 
C TNF-a 5 2.5 0.5 0.05 
Pi-AR n m m j j j j m j j j p m j m j u m m i — ”�匕？ 
1 2.37 266 2.36 2.74 2.25 
P-actm f T f ..V ：« • - 201 bp 
(b) 
H89 ( _ 
C 5 2.5 0.5 0.05 
1 0.97 1.1 0.93 1.04 
Fig. 39 Effects of H89 on the levels of Pi-AR and P-actin mRNA induced by TNF-a 
in astrocytes. Cells were treated with (a) 0.05 to 5 |LIM H89 for 2 hours before 
exposure to 500 U/ml TNF-a for another 2 hours or (b) 0.05 to 5 jiM H89 alone for 2 
hours. Then, total RNA was extracted and followed by RT-PCR as described in 




H89 (|iM) + TNF-a 
I 1 
C TNF-a 5 2.5 0.5 0.05 
�、释、r，工 P 
1 3.37 3.3 3.15 3.21 3.39 
P-actin � 贊 • 警 . _ 201 bp 
(b) 
H89 (|iM) 
C 5 2.5 0.5 0.05 
p2-AR - 456 bp 
1 1.16 1.25 1.19 1.18 
P-actin - 201 bp 
Fig. 40 Effects of H89 on the levels of P2-AR and P-actin mRNA induced by TNF-a 
in astrocytes. Cells were treated with (a) 0.05 to 5 [iM H89 for 2 hours before 
. .exposure to 500 U/ml TNF-a for another 2 hours or (b) 0.05 to 5 ^iM H89 alone for 2 
hours. Then, total RNA was extracted and followed by RT-PCR as described in 
Section 2.2. Data presented are representatives of three separate experiments with 
similar results. 
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3.4.4. Effects of TNF-a on the expression of (3i- and P2-AR protein 
In this study, we observed that both P-AR subtypes were found in rat 
astrocytes (Fig. 41), supporting studies that astrocytes expressed both subtypes (Morin 
et al, 1997; Salm and McCarthy, 1989; Trimmer and McCarthy, 1986). Upon 
exposure to TNF-a, the induction of Pi-AR protein was clearly observed at 3 hours, 
peaked at 6 hours and remained very high even after 72 hours (Fig. 41), while P2-AR 
was induced as early as 45 minutes and the induction sustained for 72 hours (Fig. 41). 
Therefore, this is in agreement with the RT-PCR results that P2-AR responded to the 
TNF-a quicker than Pi-AR. 
3.4.5. Effects of other cytokines on the expression of pi- and P2-AR mRNA 
IFN-y and IL-6 did not induce the pi-AR gene expression (Fig. 42), while 
IL - l a and IL-ip, at lower concentrations (0.1-1 ng/ml), had stimulatory effects on 
Pi-AR gene expression, but higher concentrations were less effective (Fig. 43). For 
p2-AR, IFN-y increased the mRNA level particularly at 10 ng/ml (Fig. 44), while IL-6 
showed induction, at all concentrations tested, and the maximum induction was 
obtained with 1 ng/ml (Fig. 44). I L - l a and IL-lp were potent in stimulating P2-AR 
gene expression (Fig. 45). IL-ip was more potent than IL- l a at all concentrations 
tested. In addition, IL-6 and IFN-y, which did not stimulate astrocyte proliferation 
‘ 100 
(Fig. 6), were unable to induce (3i-AR gene expression. Altogether, these data suggest 
that Pi- and P2-AR genes are differently regulated by these cytokines and that TNF-a 
was more potent to induce P-AR expression in the present study. 
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Time treatment of 500 U/ml TNF-a (min) 
C 45 90 180 360 1440 2880 4320 
Pi-AR .柳.—• 一—丨“綱•““一. 一丨一丨丨丨-丨‘—50 kda 
1 0.88 1.25 2.76 3.7 2.53 2.92 2.77 
[32"A.R. 狄聊?.f wft^wft^—. m m m m ^ �� —47 kdS 
1 2.71 2.47 2.81 3.19 3 3.22 3.3 
Fig. 41 Effects of TNF-a on the levels of Pi- and P2-AR protein in astrocytes. Cells 
were treated with 500 U/ml TNF-a for 45 minutes to 72 hours and total protein was 
extracted and followed by Western blot analysis as described in Section 2.2. Data 




C 100 10 1 0.1 
- 二 ' - >� .St. 
PI-AR ： . ‘ 姆 i ^ ^ j t � 376 bp 
1 1 0.98 0.96 0.96 
P-actin 
� ItolHIIIIlriHilMIHIIIldHtaHHHMHJBMHilllHMlAMlBa^^^ 一 2U1 bp 
IL-6 (ng/ml) 
C 100 10 1 0.1 
Pi , - ' \ - 376 bp 
1 0.95 0.96 0.98 1 
Fig. 42 Effects of IFN-y and IL-6 on the levels of pi-AR and P-actin mRNA in 
astrocytes. Cells were treated with 0.1 to 100 ng/ml IFN-y or IL-6 for 2 hours. Then, 
total RNA was extracted and followed by RT-PCR as described in Section 2.2. Data 
presented are representatives of three separate experiments with similar results. 
. 1 0 3 
IL- la (ng/ml) 
C 100 10 1 0.1 
pi-AR - 376 bp 
1 0.99 0.8 1.46 2.26 
P-actin - 201 bp 
IL-ip (ng/ml) 
C 100 10 1 0.1 
S犬 一 bp 
1 1.03 1.16 1.69 2.78 
P-actin “ | P j • 響 _ 201 ^^ 
Fig. 43 Effects of IL- la and IL-ip on the levels of Pi-AR and P-actin mRNA in 
astrocytes. Cells were treated with 0.1 to 100 ng/ml IL- la or IL-ip for 2 hours. Then, 
total RNA was extracted and followed by RT-PCR as described in Section 2.2. Data 




C 100 10 1 0.1 
P2-AR - - - . � 二 厂 " . • 八• 、 ： • - - 4 5 6 bp 
1 1.23 2.57 1.66 1.76 
P-actin � . ： 置 1 肩,豐 l i l l I I ul J . j l g i P i ^ f l _ 201 bp 
IL-6 (ng/ml) 
C 100 10 1 0.1 
B”AR ^ m ^ l ^ ^ ^ ^ ^ M I P i ' W M i _ 456 bD 
1 2.53 1.99 3.29 2.72 
Fig. 44 Effects of IFN-y and IL-6 on the levels of P2-AR and p-actin mRNA in 
astrocytes. Cells were treated with 0.1 to 100 ng/ml IFN-y or IL-6 for 2 hours. Then, 
total RNA was extracted and followed by RT-PCR as described in Section 2.2. Data 
presented are representatives of three separate experiments with similar results. 
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I L - l a (ng/ml) 
C 100 10 1 0.1 
P2-AR 、：. . T . , ：； > - 456 bp 
1 3.13 3.29 1.98 2.52 
p_aetin 響 _ _ ! ! _ _ ‘ 丨 “ ' _ ^^^ bp 
IL-ip (ng/ml) 
C 100 10 1 0.1 
p2-AR f … / \ : … ‘ - 4 5 6 bp 
1 4.77 5.83 3.61 5.43 
P - - •丨.丨丨丨.丨• 9 " • • 1 一 
Fig. 45 Effects of I L - l a and IL-1 (3 on the levels of P2-AR and p-actin mRNA in 
astrocytes. Cells were treated with 0.1 to 100 ng/ml IL - l a or IL-ip for 2 hours. Then, 
total RNA was extracted and followed by RT-PCR as described in Section 2.2. Data 
presented are representatives of three separate experiments with similar results. 
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3.5. Interactions between TNF-a and P-adrenergic mechanism in 
astrocytes 
We previously demonstrated that P-agonist could suppress the TNF-a-induced 
proliferation, and that TNF-a induced Pi- and P2-AR mRNA and protein expressions 
in cultured rat astrocytes, suggesting that they are related in astrocytes. In this section, 
we examined whether p-adrenergic mechanism exerted any effect on endogenous 
TNF-a and TNFR expressions, so as to characterize their interrelationships. We 
treated astrocytes with selective (3-agonists and -antagonists to find out the roles 
played by the two P-AR subtypes on the genes expression. 
3.5.1. Effects of p-agonists and -antagonists on the TNF-a-induced endogenous 
TNF-a expression in astrocytes 
3.5.1.1. Effects of ISO and PROP on the expression of TNF-a mRNA 
Astrocytes treated with 0.05-50 |iM p-agonist ISO did not alter the TNF-a 
mRNA expression (Fig. 46a), and (3-antagonist PROP alone did not induce the TNF-a 
gene (Fig. 46b). However, PROP strongly enhanced the TNF-a-induced TNF-a 
mRNA level (Fig. 46a). At 0.5 and 2.5 of propranolol, the increases were almost 
3-folds. As activation of p-adrenergic mechanism has been reported to activate 
adenylate cyclase (Rosenberg and Li, 1995), we examined the role played by cAMP 
‘ 107 
on astrocytes. Cells were cultured with either 0.5 and 5 fiM ISO or 50 and 500 i^M 
dbcAMP and 500 U/ml TNF-a for 2 hours. Both ISO and dbcAMP showed 
suppressive effect on the TNF-a-induced TNF-a mRNA expression (Fig. 47). 
Therefore, P-ARs may exert a negative feedback effect on the TNF-a-induced TNF-a 
gene expression through cAMP elevation. 
3.5.1.2. (3-AR subtypes involved in the TNF-a-induced TNF-a mRNA expression 
Similar to that of ISO, selective Pi- and P2-agonists, DOB and PROC 
respectively, applied to astrocytes did not induce the TNF-a gene expression (data not 
shown). To ascertain the effect of P-AR blockade on the TNF-a-induced TNF-a gene 
expression, astrocytes were treated with ATEN or ICI before exposure to TNF-a. It 
was observed that treating either antagonist alone did not induce the TNF-a gene 
expression (Fig. 48b). Blocking either Pi- or P2-AR further increased the 
TNF-a-induced TNF-a mRNA level and the effect of P2-AR blocker seemed to be 
more effective (Fig. 48a),. 
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(a) 
ISO ( _ PROP ( _ + TNF-a 
1 ‘ I . ‘ I 
C 50 5 0.5 0.05 TNF-a 10 2.5 0.5 0.05 
雾 ： r - ^ i - 4 1 1 bp 
1 0.14 0.64 1.11 1.29 11.64 21.93 38.2 39.33 25.36 
P - t i n - . 0 1 Hn 
(b) 
PROP ( _ 
C 10 2.5 0.5 0.05 
TNF-a ‘ - . ‘，’:;、/ - 4 1 1 bp 
1 0.56 0.77 0.9 0.91 
Fig. 46 Effects of ISO and PROP on the levels of TNFa and p-actin mRNA in 
astrocytes. Cells were treated with (a) 0.05-50 |iM ISO or 0.05-10 ^iM PROP for 2 
hours in the presence or absence of 500 U/ml TNF-a for an extra 2 hours or (b) 
0.05-10 |aM PROP alone for 2 hours. Then, total RNA was extracted and followed by 
RT-PCR as described in Section 2.2. Data presented are representatives of three 
separate experiments with similar results. 
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ISO ( _ + TNF-a dbcAMP ( _ + TNF-a 
C TNF-a 5 0.5 500 50 
TNF ‘ *-•'•''-"'^ y A" 二： j ' y I.I  " • � _ 411 b 
1 40.83 15.47 22.54 23.46 14.47 
P-actin M . 爆 , _ 201 bp 
Fig. 47 Effects of ISO and dbcAMP on the levels of TNF-a and p-actin mRNA 
induced by TNF-a. Cells were treated with either 0.5 and 5 fiM ISO or 50 and 500 
laM dbcAMP, and 500 U/ml TNF-a for 2 hours. Then, total RNA was extracted and 
followed by RT-PCR as described in Section 2.2. Data presented are representatives of 
three separate experiments with similar results. 
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(a) 
ATEN (nM) + TNF-a ICI (nM) + TNF-a 
I — — ‘ 1 I — — ‘ 1 
C TNF-a 1000 100 10 1 1000 100 10 1 
• - a • 冒 - t S - 4 1 1 bp 
1 6.65 8.33 7.12 6.76 5.48 8.03 8.95 8.86 6.65 
P-actin E M 驅 • • T F J ^ ， • 严 • . 署 - 730 bp 
HHBBHHHHMHHHHHHHHHHHHHBMHHHBHHMMHMHNHMHHHilHHMMHi 
(b) 
ATEN (nM) ICI (nM) 
1 ‘ 1 I ‘ ^ - n 
C 1000 100 10 1 1000 100 10 1 
爾 1 - " I I I " I I I “ 11 I I I - 動 p 
1 0.78 0.81 1.05 1.06 0.88 0.91 0.85 0.9 
P-actin 警 • 警 _ 警 _ | | ! — . . 
Fig. 48 Effects of ATEN and ICI on the levels of TNF-a and p-actin mRNA in 
astrocytes. Cells were treated with (a) 1-1000 nM ATEN or ICI for 2 hours before 
exposure to 500 U/ml TNF-a for another 2 hours or (b) 1-1000 nM ATEN or ICI 
alone for 2 hours. Then, total RNA was extracted and followed by RT-PCR as 
“descr ibed in Section 2.2. Data presented are representatives of three separate 
experiments with similar results. 
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3.5.2. Effects of P-agonists and -antagonists on the TNF-a-induced TNFRs 
expressions in astrocytes 
3.5.2.1. Effects of ISO and PROP on the expression of TNFRs mRNA 
Astrocytes incubated with various concentrations of ISO did not alter the 
TNF-R2 mRNA level much (Fig. 49a). Also, no effects on TNF-Rl expression were 
observed (Fig. 49a). In agreement with this finding, propranolol did not affect the 
TNF-a-induced TNFRs genes expression (Fig. 49a). Propranolol alone also had no 
effect on the expression of TNFRs (Fig. 49b). 
To ascertain the role played by p-adrenergic mechanism in the TNF-a-induced 
TNFRs genes,, astrocytes were cultured with 0.5 and 5 |iM ISO or 50 and 500 
dbcAMP in the presence of 500 U/ml TNF-a. ISO had about 60% inhibition on the 
TNF-a-induced TNF-R2 gene expression, but no effect on TNF-Rl expression was 
observed (Fig. 50). On the other hand, dbcAMP slightly enhanced the inducing effect 
of TNF-a on TNF-R2 gene (Fig. 50). Therefore, ISO also had negative effect on the 
TNF-a-induced TNF-R2 gene expression via an undefined mechanism in astrocytes. 
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(a) 
ISO (luiM) PROP (|iM) + TNF-a 
I ‘ 1 , — — ‘ , 
C 50 5 0.5 0.05 TNF-a 10 2.5 0.5 0.05 
TNF-Rl - 322 bp 
BWWlWll^^^^^WWlHIIWl^ i^^ S^^ S^^Mife^^ •躍.w^i^mmBBlimilllllWHBIHIHIHHIIIIHIHIIHHlBllHIIBIIHlim 
1 1.1 1.04 1.12 1.18 1.19 1.18 1.11 1.13 1.02 
. ..tMfilifrli^lil^P^rri r r ' l f i A n f i t i i n ^ ^ 
1 1.21 1.14 1.14 1.22 2.99 3.34 3.16 2.53 3.22 
— 2 0 1 bp 
(b) 
PROP ( _ 
C 10 2.5 0.5 0.05 
T M F R I U y ' � * � …？ 免 
T . R 1 •• , - 3 2 2 bp 
1 0.92 1.04 1.07 1.04 
—aIIIMMIPWWWWWiliiHWiWiWMIIWgwiiMllIB———i 
1 0.94 1.05 1.02 1.02 
Fig. 49 Effects of ISO and PROP on the levels of TNF-Rl, -R2 and P-actin mRNA 
in astrocytes. Cells were treated with (a) 0.05-50 ^iM ISO or 0.05-10 |aM PROP for 2 
hours before exposure to 500 U/ml TNF-a for another 2 hours or (b) 0.05-10 pM 
PROP alone for 2 hours. Then, total RNA was extracted and followed by RT-PCR as 
described in Section 2.2. Data presented are representatives of three separate 
experiments with similar results. 
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ISO (i^M) + TNF-a dbcAMP _ ) + TNF-a 
C TNF-a 5 0.5 500 50 
TNF-Rl 复 i v i ^ - - ‘、 一 322 bp 
1 1.11 1.04 1.01 1.01 1.06 
TNF-R2 - 256 bp 
• • • • v W K ^ r i ^ i i H i i i i i i M B H r i l 
1 1.67 1.03 0.98 1.87 2.13 
P-actin - 201 bp 
Fig. 50 Effects of ISO and dbcAMP on the levels of TNF-Rl, -R2 and P-actin 
mRNA induced by TNF-a. Cells were treated with either 0.5 and 5 |j,M ISO or 50 and 
500 i^ M dbcAMP, and 500 U/ml TNF-a for 2 hours. Then, total RNA was extracted 
and followed by RT-PCR as described in Section 2.2. Data presented are 
representatives of three separate experiments with similar results. 
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3.5.2.2. (3-AR subtypes involved in the TNF-a-induced TNFRs mRNA expression 
It was observed that DOB and PROC did not affect the expression of TNF-Rl 
and -R2 genes (results not shown). To verify, astrocytes were treated with selective 
pi- and p2-antagonists, ATEN and ICI, respectively, before exposure to TNF-a. 
Treatment of either blocker did not have any effect (Fig. 51b). Blocking either Pi- or 
P2-AR enhanced, to varying degrees, the TNF-a-induced TNF-R2 gene expression 
(Fig. 51a). The effect with (32-antagonist was more prominent. Together with the 
previous findings, p-AR could regulate the TNF-a-induced TNF-R2 gene expression, 




ATEN (nM) + TNF-a ICI (nM) + TNF-a 
I ^ ‘ ^ I I ‘ I 
C TNF-a 1000 100 10 1 1000 100 10 1 
TNF-R2 _ 256 bp 
1 2.23 2.95 2.78 2.67 2.41 3.3 3.44 3.4 2.86 
P-actin I K ^ g ^ . : . 置 ， J g l 繩 - 201 bp 
(b) 
ATEN (nM) ICI (nM) 
, — — ‘ — — . 1 — — ^ ― n 
C 1000 100 10 1 1000 100 10 1 
TNF-R2 _ ^^^ ^^ 
1 1.15 1.06 1.02 1.03 1.1 1.17 0.9 1.21 
— r r z r r r r ^ 卜 'bp 
Fig. 51 Effects of ATEN and ICI on the levels of TNF-R2 and P-actin mRNA in 
astrocytes. Cells were treated with (a) 1-1000 nM ATEN or ICI for 2 hours before 
exposure to 500 U/ml TNF-a for an extra 2 hours or (b) 1-1000 nM ATEN or ICI 
alone for 2 hours. Then, total RNA was extracted and followed by RT-PCR as 
„ described in Section 2.2. Data presented are representatives of three separate 
experiments with similar results. 
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3.6. Effects of TNF-a on the expression of transcription factors in 
astrocytes 
As transcription factors and early genes are usually induced during cell 
proliferation and differentiation (Angel and Karin, 1991), we examined the effect of 
TNF-a on these so-called third messengers. The early genes have been found to be 
upregulated during brain injury (Cook et al, 1998; Akins et al, 1996) and NFKB, a 
dimeric transcription factor consisting of p50 and p65 subunits is activated by 
cytokines (Karin and Lin, 2002). 
In this study, two early genes, c-fos and c-jun, are chosen for examination. 
Their oncoproteins, once activated, can dimerize and form the transcription factor 
AP-1, which affects the expression of target genes (Herdegen and Leah, 1998). On the 
other hand, the p50 subunit of N F K B was selected as it contains a D N A binding 
domain that, once activated, binds to NFicB-acting sequence of target genes (Van 
Antwerp et al., 1998). Thus, it was used for the determination of the degree of 
activation. 
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3.6.1. Effects of TNF-a on c-fos, c-jun and NFKB/p50 expressions 
Our preliminary results found that 500 U/ml TNF-a induced the expression 
of c-fos and c-jun genes in time-dependent manners (Fig. 52). The mRNA level of 
c-fos was increased as early as 5 minutes, peaked at 30 minutes and at this time the 
level was greater than 3-folds, then descended below the basal level (Fig. 52). The 
decline at longer periods of exposure maybe due to autorepression of c-fos gene by 
c-Fos, which results in rapid breakdown of its mRNA (Chen et al” 1994; Gius et al., 
1990). The mRNA level of c-jun also peaked at 30 minutes and the increase was 
about 2.5-folds (Fig. 52). Its mRNA expression profile coincided with that of c-fos, 
indicating that transcription factor AP-1 is likely to be formed. 
The protein levels of c-Fos and c-Jun were very low in unstimulated 
astrocytes (Fig. 53). Upon exposure to TNF-a, the c-Fos and c-Jun expressions were 
stimulated time-dependently, and higher than control at 72 hours (Fig. 53). In 
addition, c-Jun was more susceptible to the TNF-a induction as it was induced 
quicker and at a greater extent than c-Fos. This finding confirmed the RT-PCR 
results that the c-fos and c-jun genes (Fig. 52) were translated into their 
corresponding proteins. Besides, their expression profiles were congruent that AP-1 
is likely to be formed in response to TNF-a stimulation. 
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Besides, NFKB/p50 mRNA expression was gradually induced by TNF-a and 
the optimal stimulation was observed at around 2-4 hours, remained high even after 
48 hours (Fig. 54). This indicates that NFKB/p50 can be induced by TNF-a and may 
participate in TNF-a-induced astrocyte proliferation. 
3.6.2. Effects of other cytokines on the expression of NFKB/p50 mRNA 
In rat astrocytes, IFN-y did not show significant induction to the expression 
of NFKB/P50 gene (Fig. 55), while IL-6 slightly increased the mRNA level of 
N F K B / P 5 0 (Fig. 55). Different from I L - 6 and IFN-y , both IL-1 a and I L - I P were 
more effective, particularly IL-ip, in stimulating the NFKB/p50 gene expression (Fig. 
56). Notably, TNF-a, IL-1 a and IL-ip, which induced the proliferation of astrocytes, 
had very strong induction in NFKB/p50 gene. Therefore, astrocyte proliferation 
maybe related to the N F K B induction. Besides, we found that all of these cytokines, 
to varying degrees, stimulated both c-fos and c-jun genes expression (results not 
shown). 
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Time treatment of 500 U/ml TNF-a (min) 
C 5 10 20 30 60 120 240 1440 2880 
c-fos > ‘ 厂 管 、 管 警 净 ^ ^ - 273 bp 
1 1.44 1.86 2.61 3.27 2.47 1.21 0.86 0.92 0.76 
— - - b p 
1 1.15 1.08 1.62 2.48 1.77 1.51 1.22 1.01 0.78 
p-actin ‘ t t ？ t - 201 bp 
‘ . M i -njsr--- - • WSM 
Fig. 52 Effects of TNF-a on the levels of c-fos, c-jun and p-actin mRNA in 
astrocytes. Cells were treated with 500 U/ml TNF-a for 5 minutes to 48 hours and 
total RNA was extracted and followed by RT-PCR as described in Section 2.2. Data 
presented are representatives of three separate experiments with similar results. 
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Time treatment of 500 U/ml TNF-a (min) 
C 45 90 180 360 1440 2880 4320 
c-Fos . “ - 、 . ： 楼 爹 * � - 辦 ‘ - 6 2 kda 
» 、、•、•• ‘ 
1 1.23 1.21 1.56 1.35 1.78 1.9 1.87 
c^Jufi ，拟 彻譯雄^辦^^ Stawwf^ � 屬 一 39 kda 
1 1.67 1.71 1.86 2.12 2.79 3.15 3.62 
Fig. 53 Effects of TNF-a on the levels of c-Fos and c-Jun protein in astrocytes. 
Cells were treated with 500 U/ml TNF-a for 45 minutes to 72 hours and total protein 
was extracted and followed by Western blot analysis as described in Section 2.2. Data 
presented are representatives of three separate experiments with similar results. 
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Time treatment of 500 U/ml TNF-a (min) 
C 5 10 20 30 60 120 240 1440 2880 
N F K B / P S O - 8 2 3 b p 
1 1.09 1.68 2.44 2.77 3.68 4.87 5.25 2.9 3.25 
P-actin _ 201 bp 
Fig. 54 Effects of TNF-a on the levels of NFKB/p50 and p-actin mRNA in 
astrocytes. Cells were treated with 500 U/ml TNF-a for 5 minutes to 48 hours and 
total RNA was extracted and followed by RT-PCR as described in Section 2.2. Data 
presented are representatives of three separate experiments with similar results. 
• 1 2 2 
IFN-y (ng/ml) 
C 100 10 1 0.1 
• | | | | | | i i i i i l _ _ | _ _ i l i i i II I i i l i l l | i _ | — 
N F K B / P 5 0 U U I G G L L I G G ' F C S ^ g g l J S I - 8 2 3 b p 
1 1.03 1.06 1 1 
P-actin 【 二 . 置 一 ' 1 "".. " I I I , 曙 — _ 201 bp 
IL-6 (ng/ml) 
C 100 10 1 0.1 
N F K B / P 5 0 - 8 2 3 b p 
1 1.26 1.12 2.11 1.68 
Fig. 55 Effects of IFN-y and IL-6 on the levels of NFKB/p50 and P-actin mRNA in 
astrocytes. Cells were treated with 0.1 to 100 ng/ml IFN-y or IL-6 for 2 hours. Then, 
total RNA was extracted and followed by RT-PCR as described in Section 2.2. Data 
presented are representatives of three separate experiments with similar results. 
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IL- la (ng/ml) 
C 100 10 1 0.1 
N F K B / P S O 『 I G 、 — ， 【 - 嶋 
1 2.32 1.54 1.5 2.78 
-actin p — 翼 2 0 1 bp 
IL-ip (ng/ml) 
C 100 10 1 0.1 
-KB/pSO " : ’ e : 重 ： 黨 〕 - 8 2 3 bp 
1 3.36 3.28 3.01 3.05 
P-actin W" ^ r l E l ^ ^ - 201 bp 
Fig. 56 Effects of IL- la and IL-ip on the levels of NFKB/p50 and p-actin mRNA in 
astrocytes. Cells were treated with 0.1 to 100 ng/ml IL- la or IL-lp for 2 hours. Then, 
total RNA was extracted and followed by RT-PCR as described in Section 2.2. Data 
presented are representatives of three separate experiments with similar results. 
y ' 
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3.6.3. TNFR subtypes involved in the TNF-a-induced c-fos, c-jun and NFKB/p50 
mRNA expressions 
In this section, we demonstrated that blocking either TNFR subtype alone was 
sufficient to induce the mRNA expression of c-jun, but no significant effect was 
observed in that of c-fos (Figs. 57b & 58b). On the other hand, blocking both TNF-Rl 
and -R2 could reduce the mRNA levels of the two early genes induced by TNF-a. For 
c-fos, its mRNA level was only reduced with higher concentrations of TNF-R2 
antibody (2500-5000 ng/ml) (Fig. 57a & 58a), while for c-jun mRNA level was 
reduced with lower concentrations (50-500 ng/ml) of both antibodies (Fig. 57a & 58a). 
Therefore, it seems that both subtypes are involved in the TNF-a-induced c-fos and 
c-jun genes expression. 
For N F K B / P 5 0 gene, treatment with either T N F R antibody alone did not affect 
its mRNA level (Figs. 59b & 60b). Treating both receptor antibodies before TNF-a 
induction did not alter the TNF-a-induced NFKB/p50 mRNA level (Figs. 59a & 60a). 




TNF-Rl antibody (ng/ml) + TNF-a 
I ‘ 1 
C TNF-a 5000 2500 500 50 
1 1.48 1.12 1.36 1.4 1.46 
c-j膽 .、冗 - 427 bp 
1 1.57 0.88 1.34 1.42 0.76 
P-actin 邏 - 2 m Hn . 
(b) 
TNF-Rl antibody (ng/ml) 
C 5000 2500 500 50 
一 ‘ B ： ^ ^ ^ * ^ - • ‘ - 2 7 3 bp 
1 0.94 1.03 1.11 1.08 
C-jun � - ？ • r - J B H K ' - 427 bp 
1 1.87 1.7 1.46 1.34 
p-acun iM^ i^in (Kinr mr riii^ Mli iJBii " i lMi i i…. . .— 201 DD 
MHIMIHHIIIIIIIMHMnilllllllHMIinHIIIIHIIIMHHHnaiHMIHHHIl ‘ 
Fig. 57 Effects of TNF-Rl antibody on the levels of c-fos, c-jun and P-actin mRNA 
induced by TNF-a in astrocytes. Cells were treated with (a) 50 to 5000 ng/ml 
TNF-Rl antibody for 2 hours before exposure to 500 U/ml TNF-a for another 2 hours 
or (b) 50 to 5000 ng/ml TNF-Rl antibody alone for 2 hours. Then, total RNA was 
extracted and followed by RT-PCR as described in Section 2.2. Data presented are 
representatives of three separate experiments with similar results. 
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(a) 
TNF-R2 antibody (ng/ml) + TNF-a 
1 — — ‘ 1 
C TNF-a 5000 2500 500 50 
c-fos j ^ j ^ J j ^ ^ ^ j m i U B Z l ^ l ^ i m J I ^ ^ U I ^ ^ - 273 bp 
1 1.43 1.18 1.21 1.42 1.47 
_ _ 427 bp 
1 1.5 0.92 0.81 0.71 0.95 
P-actin — zuiDp 
(b) 
TNF-R2 antibody (ng/ml) 
C 5000 2500 500 50 
筹 f 霄 … 、 ’ - 梦 着 ； 曹 W T ' �靈 書 ‘ I 加 ” - � • � �. 崎 — 4 - 2 7 3 bp 
1 0.83 1.02 1.1 1.04 
c-jun 圓 — i f c m i " ^ W i i l i r ^ l ' . . . . . . . � - 4 2 7 bp 
1 2.01 1.94 2.16 2.06 
Fig. 58 Effects of TNF-R2 antibody on the levels of c-fos, c-jun and P-actin mRNA 
induced by TNF-a in astrocytes. Cells were treated with (a) 50 to 5000 ng/ml TNF-R2 
antibody for 2 hours before exposure to 500 U/ml TNF-a for another 2 hours or (b) 50 
to 5000 ng/ml TNF-R2 antibody alone for 2 hours. Then, total RNA was extracted and 
followed by RT-PCR as described in Section 2.2. Data presented are representatives of 
three separate experiments with similar results. 
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(a) 
TNF-Rl antibody (ng/ml) + TNF-a 
I ‘ 1 
C TNF-a 5000 2500 500 50 
1 1.4 1.46 1.36 1.4 1.33 
p-actin - 201 bp 
(b) 
TNF-Rl antibody (ng/ml) 
C 5000 2500 500 50 
N F K B / P 5 0 丄，丨 _ P 
1 1.16 1.1 1.01 1.12 
P-actin — 201 bp 
Fig. 59 Effects of TNF-Rl antibody on the levels of N F K B and P-actin mRNA 
induced by TNF-a in astrocytes. Cells were treated with (a) 50 to 5000 ng/ml 
., TNF-Rl antibody for 2 hours before exposure to 500 U/ml TNF-a for another 2 hours 
or (b) 50 to 5000 ng/ml TNF-Rl antibody alone for 2 hours. Then, total RNA was 
extracted and followed by RT-PCR as described in Section 2.2. Data presented are 
representatives of three separate experiments with similar results. 
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(a) 
TNF-R2 antibody (ng/ml) + TNF-a 
I ‘ 1 
C TNF-a 5000 2500 500 50 
1 1.41 1.44 1.49 1.42 1.36 
p-actin L M l X M ^ ^ ^ ^ H t t i ^ H M B M i “ “ ^ 
(b) 
TNF-R2 antibody (ng/ml) 
C 5000 2500 500 50 
N F K B / P 5 0 操 _ 8 2 3 b p 
1 1.11 1.03 1.01 1.02 
" p p i """I I 
Fig. 60 Effects of TNF-R2 antibody on the levels of N F K B and P-actin mRNA 
induced by TNF-a in astrocytes. Cells were treated with (a) 50 to 5000 ng/ml TNF-R2 
„ antibody for 2 hours before exposure to 500 U/ml TNF-a for another 2 hours or (b) 50 
to 5000 ng/ml TNF-R2 antibody alone for 2 hours. Then, total RNA was extracted and 
followed by RT-PCR as described in Section 2.2. Data presented are representatives of 
three separate experiments with similar results. 
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3.7. Effects of TNF-a on the expression of iNOS in astrocytes 
As mentioned in the introduction, NO has been reported to be produced after 
various neurological diseases; therefore, it may promote astrogliosis and glial scarring. 
In fact, NO is an important second messenger in the CNS; for example, it behaves as a 
neurotransmitter and guanylyl cyclase activator (Davis et al.’ 2001). In disease 
conditions, NO is mainly generated by the action of inducible form of NOS (iNOS), 
which is induced by various immunogenic stimuli, such as bacterial LPS and 
cytokines (Munoz-Femandez and Fresno, 1998). It has been reported that 
transcription factors like AP-1 and N F K B are involved in the transcriptional activation 
of iNOS (Nishiya et al., 2000; Eberhardt et al.’ 1996). We found that TNF-a induced 
the expression of c-fos, c-jun and NFKB/p50, so the effect of TNF-a on iNOS gene 
was examined. 
3.7.1. Effects of TNF-a the expression of iNOS mRNA 
We found that TNF-a dose-dependently induced iNOS mRNA expression 
(Fig. 61) and the highest induction was obtained with 1000 U/ml TNF-a. In addition, 
the time-course effect of 500 U/ml TNF-a on iNOS expression was examined. 
Basically, iNOS mRNA level was only weakly detected in astrocytes. In the presence 
of 500 U/ml TNF-a, a clear induction was observed after 2 hours and this maintained 
‘ 1 3 0 
even at 48 hours (Fig. 62). The optimal induction was observed at 4 hours and at the 
time the level was greater than 15-folds of the control. 
3.7.2. TNFR subtypes involved in the TNF-a-induced iNOS mRNA expression 
Treating astrocytes with TNF-Rl antibody alone at 50 ng/ml slightly induced 
the iNOS mRNA expression (Fig. 63b). On the other hand, treatment with TNF-R2 
antibody significantly stimulated the iNOS mRNA expression (Fig. 64b). At 5000 
ng/ml TNF-R2 antibody, the increase was above 10-folds. This suggests that iNOS 
gene expression can be mediated through both TNFR subtypes. 
Besides blocking the TNF-Rl before exposure to TNF-a further enhanced the 
action of TNF-a on the iNOS expression slightly (Fig. 63a), while blocking the 
TNF-R2 suppressed that the iNOS expression and almost 80% inhibition was 
observed at 50 ng/ml TNF-R2 antibody (Fig. 64a). Therefore, the above finding 
indicates that the TNF-a-induced iNOS gene expression is mainly regulated through 
TNF-R2 in rat astrocytes. 
J ‘ 
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Dose treatment of TNF-a (U/ml) 
C 10 100 500 1000 
1 2.99 5.06 6.7 9.68 
P - a c 如 - 2 0 1 bp 
Fig. 61 Effects of TNF-a on the levels of iNOS and p-actin mRNA in astrocytes. Cells 
were treated with 10 to 1000 U/ml TNF-a for 2 hours and total RNA was extracted and 
followed by RT-PCR as described in Section 2.2. Data presented are representatives of 
three separate experiments with similar results. 
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Time treatment of 500 U/ml TNF-a (min) 
C 5 10 20 30 60 120 240 1440 2880 
iNOS - 730 bp 
1 1 0.94 0.99 0.94 1.28 2.74 15.65 11.25 5.94 
P-actin e 1 yt % " § " % - - 201 bp 
Fig. 62 Effects of TNF-a on the levels of iNOS and p-actin mRNA in astrocytes. 
Cells were treated with 500 U/ml TNF-a for 5 minutes to 48 hours and total RNA was 
extracted and followed by RT-PCR as described in Section 2.2. Data presented are 





TNF-Rl antibody (ng/ml) + TNF-a 
I ‘ 1 
C TNF-a 5000 2500 500 50 
iNOS 赛 … 1 � ’ - 730 bp 
1 20.35 24.48 26.98 26.83 28.41 
P-actin , • 響 - 201 bp 
(b) 
TNF-Rl antibody (ng/ml) 
C 5000 2500 500 50 
iNOS — r . . . . . ‘ . ‘ . . — — 酬 【 . … 
1 1.03 1.61 0.72 2.41 
� p-actin 'I 丨‘g""-' I I I 冒 曜 , 一 201 bp 
Fig. 63 Effects of TNF-Rl antibody on the levels of iNOS and P-actin mRNA 
induced by TNF-a in astrocytes. Astrocytes were treated with (a) 50 to 5000 ng/ml 
TNF-Rl antibody for 2 hours before exposure to 500 U/ml TNF-a for another 2 hours 
or (b) 50 to 5000 ng/ml TNF-Rl antibody alone for 2 hours. Then, total RNA was 
extracted and followed by RT-PCR as described in Section 2.2. Data presented are 
representatives of three separate experiments with similar results. 
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(a) 
TNF-R2 antibody (ng/ml) + TNF-a 
1 ‘ 1 
C TNF-a 5000 2500 500 50 
1 36.68 24.21 30.13 28.32 8.04 
P-actin * ••^jaJHiiiiiiillliii^i^^ - � P 
(b) 
TNF-R2 antibody (ng/ml) 
C 5000 2500 500 50 
1 11.8 2.55 2.1 5.15 
P省 tm L u i i l i J L — . 1 - 201 bp 
Fig. 64 Effects of TNF-R2 antibody on the levels of iNOS and P-actin mRNA 
induced by TNF-a in astrocytes. Cells were treated with (a) 50 to 5000 ng/ml TNF-R2 
antibody for 2 hours before exposure to 500 U/ml TNF-a for another 2 hours or (b) 50 
to 5000 ng/ml TNF-R2 antibody alone for 2 hours. Then, total RNA was extracted and 
followed by RT-PCR as described in Section 2.2. Data presented are representatives of 
three separate experiments with similar results. 
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3.7.3. Signaling pathways of the TNF-a-induced iNOS mRNA expression 
Then, we investigated the effects of PKA or PKC activation on iNOS gene 
expression. None of the PKC and PKA activators could induce the expression of 
iNOS mRNA (results not shown). To verify, we treated astrocytes with Ro-31 and 
1 
H89 before exposed to TNF-a. Both inhibitors did not alter the iNOS mRNA level 
(Figs. 65b and 66b). However, Ro-31 blocked partly, even at low concentrations, the 
TNF-a-induced iNOS mRNA level and the inhibition was about 50% at 10 nM of 
Ro-31 (Fig. 65a). On the other hand, blocking the PKA also reduced the stimulatory 
effect of TNF-a on iNOS mRNA expression, and about 75% inhibition was observed 
with 0.5 |iM of H89 (Fig. 66a). Chen's group (1998) found that PKC” is involved in 
the LPS-induced iNOS expression in primary astrocytes (Chen et al., 1998). However, 




Ro-31 (nM) +TNF-a 
I ‘ 1 
C TNF-a 1000 500 100 10 
iNOS I B B i B S m f , | | " | 一 730 bp 
1 15.14 0.73 9.97 8.52 10.01 
P-actin - 201 bp 
(b) 
Ro-31 (nM) 
C 1000 500 100 10 
- S • 减 - 7 3 0 bp 
1 1.02 1.51 0.88 1.07 
P"3ctin jjUjjjjjjijiijjjijjjjjjjj^ ^^ ^^ gjjjiijjjjjjjijiH^ jl^ j^ jj^ j^ j^ jjljjjjjjl^ j^ jlll^ jjjljjjlj^ l^ jmj^ jjjj^ l^jjjl^ j^jjjj - 201 bp 
Fig. 65 Effects of Ro-31 on the levels of iNOS and p-actin mRNA induced by 
TNF-a in astrocytes. Cells were treated with (a) 10 to 1000 |aM Ro-31 for 2 hours 
before exposure to 500 U/ml TNF-a for another 2 hours or (b) 10 to 1000 |iM Ro-31 
alone for 2 hours. Then, total RNA was extracted and followed by RT-PCR as 
described in Section 2.2. Data presented are representatives of three separate 
experiments with similar results. 
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H89 (|iM) + TNF-a 
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(b) 
H89 ( _ 
C 5 2.5 0.5 0.05 
画 『 ” . 多 1 — 1 - 雇 p 
1 0.77 0.94 0.93 1.01 
P-actin 繁 . — . - 201 bp 
Fig. 66 Effects of H89 on the levels of iNOS and P-actin mRNA induced by TNF-a 
in astrocytes. Cells were treated with (a) 0.05 to 5 \xM H89 for 2 hours before 
“ exposure to 500 U/ml TNF-a for another 2 hours or (b) 0.05 to 5 i^M H89 alone for 2 
hours. Then, total RNA was extracted and followed by RT-PCR as described in 
Section 2.2. Data presented are representatives of three separate experiments with 
similar results. 
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3.7.4. Effects of other cytokines on the expression of iNOS mRNA 
We observed that cytokine specificity existed in the cytokine-induced iNOS 
expression in astrocytes. IFN-y did not significantly enhance the iNOS mRNA 
expression, while IL-6 only had weak stimulation at 0.1 ng/ml (Fig. 67). On the other 
hand, IL- la and IL-lp exhibited very strong induction on iNOS mRNA expression, 
and that IL-ip was more effective (Fig. 68). For IL-la , iNOS level was optimally 
induced (of 18-folds) at 100 ng/ml, whereas the highest induction of IL-lp was 
observed (of about 19-folds) at 1 and 10 ng/ml. The effect of IL-1 on iNOS was 
comparable to that of TNF-a. Notably, IL-6 and IFN-y, which did not stimulate 
astrocyte proliferation (Fig. 6), did not stimulate the iNOS gene expression 
sufficiently. This indicates that astrocyte proliferation and iNOS might be related. 
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Fig. 67 Effects of IFN-y and IL-6 on the levels of iNOS and p-actin mRNA in 
astrocytes. Cells were treated with 0.1 to 100 ng/ml IFN-y or IL-6 for 2 hours. Then, 
„ total RNA was extracted and followed by RT-PCR as described in Section 2.2. Data 
presented are representatives of three separate experiments with similar results. 
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Fig. 68 Effects of IL- la and IL-1 (3 on the levels of iNOS and p-actin mRNA in 
astrocytes. Cells were treated with 0.1 to 100 ng/ml IL- la or IL-lp for 2 hours. Then, 
„ total RNA was extracted and followed by RT-PCR as described in Section 2.2. Data 
presented are representatives of three separate experiments with similar results. 
i ‘ 
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3.7.5. Effects of P-agonists and -antagonists on the TNF-a-induced iNOS 
expression 
Previously, we found that TNF-a induced the expression of P-ARs (Figs. 29 & 
30) and iNOS (Figs. 61 & 62). In this section, p-agonists and -antagonist were used to 
find out if relationships existed between TNF-a and (3-adrenergic mechanism in the 
expression iNOS gene. 
3.7.5.1. Effects of ISO and PROP on the expression of iNOS mRNA 
We found that ISO greatly increased the iNOS mRNA level by 9-folds, while 
low concentrations did not have effect (Fig. 69a). Conversely, blocking the p-ARs by 
PROP reduced the TNF-a-induced iNOS mRNA level and 60% reduction was 
observed even with 0.05 pM of PROP (Fig. 69a). PROP alone did not alter the 
expression of iNOS gene (Fig. 69b). When treating cells with ISO or dbcAMP in the 
presence of TNF-a, the iNOS mRNA level in the ISO group was greatly enhanced 
(Fig. 70); however, no significant change was found in the dbcAMP group. The above 
findings suggest that ISO induces iNOS expression via a mechanism other than that 
mediating TNF-a (Section 3.5.1). 
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3.7.5.2. B-AR subtypes involved in the TNF-a-induced iNOS mRNA expression 
To ascertain the action of ISO and roles played by the two p-AR subtypes, we 
tested the effects of DOB and PROC on iNOS mRNA expression. We found that both 
agonists only weakly induced the iNOS gene expression (Fig. 71). 
Then, we tested the effects of ATEN and ICI on the TNF-a-induced iNOS 
gene expression. Treatment of either antagonist alone did not trigger the expression of 
the iNOS mRNA (Fig. 72b). Interestingly, our preliminary results showed that 
blocking the pi-AR with 1-1000 nM ATEN before exposure to TNF-a reduced the 
iNOS mRNA level (Fig. 72a), while blocking the P2-AR with 10-1000 ICI before 
exposure to TNF-a strongly increased the iNOS mRNA level (Fig. 72a) and greater 
than 6-folds increase was observed with 10 nM of ICI. The above findings suggest 
that blocking the P2-AR enhances, while blocking the Pi-AR reduces the 
TNF-a-induced iNOS gene expression. However, further experiments have to be 
preformed to find out the role of each p-AR subtype in the TNF-a-induced iNOS 
expression. 
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Fig. 69 Effects of ISO and PROP on the levels of iNOS and p-actin mRNA in 
astrocytes. Cells were treated with (a) 0.05-50 jiM ISO or 0.05-10 \iM PROP for 2 
„ hours in the presence or absence of 500 U/ml TNF-a for another 2 hours or (b) 0.05-10 
|aM PROP alone for 2 hours. Then, total RNA was extracted and followed by RT-PCR 
as described in Section 2.2. Data presented are representatives of three separate 
experiments with similar results. 
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Fig. 70 Effects of ISO and dbcAMP on the levels of iNOS and P-actin mRNA 
induced by TNF-a. Cells were treated with either 0.5 and 5 ISO or 50 and 500 
|LIM dbcAMP, and 500 U/ml TNF-a for 2 hours. Then, total RNA was extracted and 
followed by RT-PCR as described in Section 2.2. Data presented are representatives of 
three separate experiments with similar results. 
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Fig. 71 Effects of DOB and PROC on the mRNA levels of iNOS and P-actin in 
astrocytes. Cells were treated with 5-5000 nM DOB or PROC for 2 hours. Then, total 
RNA was extracted and followed by RT-PCR as described in Section 2.2. Data 
presented are representatives of three separate experiments with similar results. 
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Fig. 72 Effects of ATEN and ICI on the levels of iNOS and P-actin mRNA in 
astrocytes. Cells were treated with (a) 1-1000 nM ATEN or ICI for 2 hours before 
‘ exposure to 500 U/ml TNF-a for another 2 hours or (b) 1-1000 nM ATEN or ICI alone 
for 2 hours. Then, total RNA was extracted and followed by RT-PCR as described in 




CHAPTER 4. DISCUSSIONS AND CONCLUSIONS 
4.1. Effects of TNF-a on astrocyte proliferation 
Elevated level of TNF-a has been observed in various neurological diseases 
and this cytokine has been found to promote astrogliosis (Shohami et al., 1999; 
Feuerstein et al, 1994; Selmaj et al., 1990), suggesting that astrocyte proliferation, 
one of the major steps of astrogliosis, and cytokine elevation are related. Results of 
the present study showed that TNF-a stimulated [^H]-thymidine incorporation in rat 
astrocytes in a dose-dependent manner (Fig. 2). Not only DNA synthesis was 
enhanced but also the number of astrocytes was also obviously increased by this 
cytokine (Fig. 1). This finding is in agreement with studies that TNF-a stimulated 
astrocyte proliferation, both in vitro and in vivo (Selmaj et al., 1990). 
Cytokines other than TNF-a have also been reported to be associated with 
astrogliosis (Wang and Shuaib, 2002; Arvin et al., 1996; Balasingam et al., 1994); 
however, their proliferative actions on astrocyte have not yet been compared. Results 
of Fig. 6 showed that IL- la and IL-P, but not IL-6 and IFN-y, could increase the 
DNA synthesis of primary rat astrocytes. This explanation is supported by studies that 
IL-1 induced astrocyte growth and astrogliosis (Giulian et al, 1988; Giulian and 
Lachman, 1985). For IL-6, Selmaj et al (1990) showed that this cytokine, both in vivo 
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and in vitro, stimulated initogensis of astrocytes. The difference of the action of IL-6 
on cell proliferation was possibly due to the source of their astrocytes, where they 
were obtained from calves, while ours were isolated from rats. Besides, TNF-a is a 
more potent cytokine in stimulating the astrocyte proliferation (Fig. 7). These imply 
that the effects of different cytokines on astrocyte proliferation are cytokine specific. 
For TNF-a to exert its effect on the target cells, the first step is to bind to the 
TNFR on cell surface. Two immunologically distinct TNFRs, TNF-Rl and -R2, have 
been identified (Tartaglia and Goeddel, 1992). In our laboratory, we found that rat 
astrocytes expressed both TNF-Rl and -R2, though TNF-Rl predominates (Lung et 
al., 2001); however, the roles played by them in astrocyte proliferation are still 
unclear. So, it is of interest to examine which subtype is responsible for the 
TNF-a-induced proliferative response. Results of Figs. 3 & 4 showed that TNF-R2, 
but not TNF-Rl，antibody could increase the number and DNA synthesis of astrocytes. 
It is likely that TNF-R2 antibody acts as an agonist. This is in agreement with reports 
that antibodies against TNF-R2 induced the proliferation of thymocytes and T cells 
‘ (Grell et al； 1998; Tartaglia et al., 1993). This finding also confirms the general idea 
that TNF-Rl mediates cytotoxicity, whereas TNF-R2 mediates mitogenic effects 
(MacEwan, 2002; Grell et al., 1998; Orlinick and Chao, 1998). However, other cell 
proliferation assays, such as neutral red assay, should be used to confirm the effect of 
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TNF-a on astrocyte proliferation. 
However, MTT assay may not be specific enough to determine cell 
proliferation, so other techniques such as neutral red assay and trypan blue exclusion 
test should be performed to further verify the action of TNF-a on the cell proliferation 
of astrocytes. 
4.2. Roles of endogenous TNF-a and TNFR in astrocyte proliferation 
Results of the present study showed that TNF-a could stimulate the expression 
of its own gene in dose- and time-dependent manners (Figs. 20 & 21). This finding is 
consistent with studies that TNF-a induced its own gene expression in astrocytes 
(Kwon et al, 1996; Benveniste et al, 1995). Owing to the presence of AUUUA repeat 
motif in the 3' untranslated regions of mRNA, which resulted in mRNA 
destabilization (Chung et al., 1992), the TNF-a gene appeared to be only transiently 
induced (Fig. 20). Indeed, the mRNA level of TNF-a was very low in unstimulated 
cells, and thus the induction of TNF-a may provide a positive feedback loop for 
TNF-a to further exert its effect on astrocyte proliferation. Figs. 27 & 28 showed that 
IL-1, but not IL-6 and IFN-y, could induce the TNF-a mRNA expression. These 
results imply that the induction of TNF-a gene in rat astrocytes is cytokine specific. 
Our results showed that activating the TNF-R2 triggered the proliferation of 
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astrocytes (Figs. 3 & 4), so we examined the possible involvement of this receptor 
subtype in the induction of TNF-a gene. To (1999) of our laboratory showed that 
antibodies against TNFR subtypes acted as antagonists rather than agonists in C6 
glioma cells when they were applied for shorter incubation time periods. Results of 
the present study showed that blocking the TNF-R2, but not TNF-Rl, almost 
abolished the TNF-a-induced TNF-a mRNA expression (Figs. 22 & 23). It is 
reasonable to conclude that TNF-R2 is more important to trigger the expression of 
TNF-a gene. 
Since TNF-R2 lacks intrinsic catalytic domains, it must acquire adaptor 
proteins for signal transduction. Several second messenger systems, including PKA, 
PKC, tyrosine kinase and MAPK, have been reported to modulate cytokines 
expressions in the brain (MacEwan, 2002; Wajant and Scheurich, 2001; Benveniste 
and Benos, 1995). In the present study, we focused mainly on the PKA and PKC 
pathways. 
Results of Fig. 24 showed that PMA could induce the expression of TNF-a 
�g e n e . This finding is in agreement with studies that induction of the TNF-a gene 
involved PKC in primary rat astrocytes (Chung et al, 1992) and human astroglioma 
cell line (Bethea et al., 1992). Results of Fig. 25 confirmed this finding that selective 
PKC inhibitor, Ro-31, attenuated the TNF-a-induced TNF-a mRNA expression. In 
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contrast, dbcAMP did not induce the expression of TNF-a mRNA (results not shown), 
and that the TNF-a-induced TNF-a gene expression was not affected by selective 
PKA inhibitor, H89 (Fig. 26). Together with the observation that TNF-a only caused 
very small increase in cAMP level in astrocytes (Norris et al., 1994), we deduced that 
PKC pathway plays a primary role in the regulation of TNF-a expression in 
astrocytes. Since various PKC isoforms including a , P, 6, 9, ” and ; are found in rat 
astrocytes (Chen et al, 1998), the isoform responsible for the TNF-a induction is the 
next target for further investigation. It has been reported that calcium ionophore 
A23187 could stimulate the production of TNF-a in astrocytes (Bethea et al., 1992). 
This finding indicates that calcium-dependent classic PKC maybe involved. 
As it is proposed that the events triggered by TNF-a are determined by the 
relative densities of the two subtypes on cell surface (MacEwan, 2002), we attempted 
to examine the effect of TNF-a on the expression of each subtype in rat astrocytes. 
Upon exposure to TNF-a, there was an induction of TNF-R2 mRNA and 
protein expressions, while TNF-Rl remained relatively unchanged (Figs. 12, 13 & 19). 
So, TNF-a selectively induced the expression of TNF-R2 in astrocytes. Our finding is 
in agreement with reports that TNF-a upregulated the expression of TNF-R2 in brain 
microglial (Dopp et al., 1997) and malignant epithelial cells (Kalthoff et al., 1993). 
Moreover, the mRNA and protein levels of TNF-Rl were higher than that of TNF-R2 
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in unstimulated astrocytes, so TNF-Rl is likely to be the predominant subtype in 
normal primary rat astrocytes. This explanation is consistent with studies that TNF-Rl 
is the principal subtype in primary astroglial cells (Dopp et al., 1997). The enhanced 
TNF-R2 expression may provide a positive feedback loop for TNF-a to further 
increase the cell proliferation of astrocytes, since activating the TNF-R2 triggered cell 
proliferation (Figs. 3 & 4). This finding also supports the proposal that events 
triggered by TNF-a depend on relative densities of each subtype on cell surface 
(MacEwan, 2002). 
Blocking the TNF-R2 could completely abolish the TNF-a-induced TNF-R2 
induction in astrocytes (Figs. 14 & 15). This suggests that TNF-R2 is critical in 
transducing the TNF-a signals to induce TNF-R2 gene expression. This observation is 
similar to preliminary report of Kalthoff's group (1993) that the induction of 
trans forming- growth factor in epithelial cancer cells was blocked by TNF-R2 
antibody. 
Results of the signal transduction studies of TNF-a showed that activating the 
PKA and PKC could increase the level of TNF-R2 mRNA (Fig. 16), but that the 
TNF-a-induced TNF-R2 mRNA was reduced by PKC inhibitor, but not by PKA 
inhibitor (Figs. 17 & 18). This explanation is consistent with studies on human 
malignant epithelial cells that PKC, but not PKA, participated in the TNF-R2 gene 
‘ 153 
induction by TNF-a (Kalthoff ef al., 1993). Although dbcAMP did stimulate TNF-R2 
expression, the induction of the TNF-R2 gene by TNF-a was independent of PKA in 
rat astrocytes. 
4.3. Interactions between TNF-a and P-adrenergic mechanism in 
astrocytes 
Besides TNF-a, P-adrenergic mechanism has also been found to be a factor 
related to astrogliosis and glial scarring (Hodges-Savola et al, 1996; Sutin and 
Griffith, 1993). As mentioned before, interaction between TNF-a action and p-AR 
has been reported in peripheral tissues, but their relationship in the CNS, particularly 
in astrocytes, is still unclear. So, we were interested to investigate whether these two 
factors are related in astrocytes. 
Unexpectedly, we observed that isoproterenol could reduce the proliferation of 
both unstimulated and TNF-a-induced astrocytes (Figs. 8 & 9), whereas propranolol 
did not affect the proliferative effect of TNF-a (Fig. 11). These imply that the 
astrocyte proliferation is not directly mediated through the p-adrenergic mechanism 
and in fact p-AR activation suppressed the TNF-a-induced cell proliferation of 
astrocytes (Fig. 9). Interestingly, our unpublished data showed that isoproterenol 
might contribute to astrogliosis by changing the morphology of astrocytes resemble 
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reactive astrocytes and enhancing GFAP expression. 
Moreover, TNF-a induced the expression of P r and P2-AR mRNA and 
protein in time- and dose-dependent manners (Figs. 29, 30 & 41). Since elevated level 
of catecholamines was observed in brain injury (Hamill et al., 1987) and p-adrenergic 
activation promoted astrogliosis (Hodges-Savola et al, 1996)，the increase in p-ARs 
densities by TNF-a might enhance astrogliosis by allowing more ligands to bind to 
p-ARs and trigger astrogliosis. This finding agrees with in vivo studies that p-AR 
densities were increased after brain injury (Mantyh et al., 1995). 
Besides, TNF-R2 was responsible for the induction of Pi- and P2-AR 
expressions (Figs. 31-34). This supports our hypothesis that interaction existed, at 
receptor level, between TNF-a and p-adrenergic mechanism. Besides, their induction 
required PKC as PMA induced the p r and P2-AR genes expression (Fig. 35) and 
Ro-31 suppressed the stimulation of TNF-a on p-ARs expressions (Figs. 37 & 38). 
This finding disagrees with studies on C6 glioma cells that PMA caused 
downregulation of P2-AR (Leavitt et al., 2001). The discrepancy maybe due to higher 
PMA dosages and different cell type they used. On the other hand, blocking the PKA 
with H89 did not alter the TNF-a-induced Pi- and P2-AR expressions (Figs. 39 & 40). 
Therefore, PKC, but not PKA, is likely to be involved. Studies on cytokine 
specificities also found that IL-1, but not IL-6 and IFN-y, was sufficient in inducing 
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the Pi-AR gene expression (Figs. 42 & 43); however, all cytokines tested were 
effective in inducing the expression of P2-AR gene. These imply that the interaction 
between cytokines and p-adrenergic mechanism is cytokine specific. 
The interrelationship between P-adrenergic mechanism and TNF-a was also 
demonstrated. It was observed that isoproterenol did not trigger the TNF-a gene 
expression, while propranolol strongly increased the TNF-a-induced TNF-a mRNA 
level (Fig. 46a). Since propranolol alone did not induce TNF-a expression (Fig. 46b), 
the TNF-a-induced TNF-a gene expression seems to be regulated by P-adrenergic 
mechanism. Furthermore, blocking either p-AR subtype was sufficient in upregulating 
the TNF-a-induced TNF-a expression (Fig. 48). It has been reported that activating 
the p2-AR reduced the endotoxin-induced TNF-a transcription in rat astrocytes 
(Nakamura et al, 1998). Interestingly, we observed that TNF-a gene expression is 
also regulated by pi-AR. 
It was seen that neither isoproterenol nor propranolol significantly affect the 
TNF-Rl and -R2 genes expression (Fig. 49). This is confirmed by selective p-agonist 
studies that none of them could alter the TNFRs mRNA level much. It was noticed 
that there was a small increase in the TNF-a-induced TNF-R2 mRNA level in cells 
pre-treated with either p-antagonist (Fig. 51). This observation might be due to the 
upregulation of endogenous TNF-a gene by p-antagonists applied to the cells (Figs. 
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46 & 48)，since TNF-a was previously found to upregulate the mRNA and protein 
expressions of TNF-R2 (Figs. 12, 13 & 19). Altogether, TNF-a action and 
P-adrenergic mechanism are closely related in rat astrocytes. 
4.4. Induction of transcription factors by TNF-a in astrocytes 
It has been reported that TNF-a can activate various transcription factors, such 
as N F K B and AP-1 (Baud and Karin, 2001; Liu et al” 1996), to regulate cell survival 
and apoptosis (Shaulian and Karin, 2001; van Antwerp et al., 1998; Karin et al., 
1997). 
Results of the present study showed that TNF-a induced the mRNA and 
protein expressions of c-fos and c-jun in cultured astrocytes (Figs. 52 & 53)， 
suggesting that astrocytes responded to TNF-a by early genes induction. Notably, the 
expression profile of c-Fos and its corresponding gene coincided with that of c-Jun, 
so AP-1 is likely to be formed. This finding supports reports that early genes 
expressions were augmented in brain injury (Cook et al., 1998; Akins et al., 1996). 
On the other hand, Fig. 54 showed that TNF-a could increase the mRNA level of 
NFKB/p50 (Fig. 54), indicating that TNF-a and N F K B maybe related in brain injury, 
as elevated N F K B level has been reported after brain injury (O'Neill and Kaltschmidt, 
1997; Selminen et al., 1996). However, further experiments are required to elucidate 
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the role played by these transcription factors in astrogliosis. 
Our RT-PCR results showed that, upon exposure to TNF-a, there was an 
induction of iNOS mRNA level in dose- and time-dependent manners (Figs. 61 & 62). 
Our finding is in agreement with studies that TNF-a enhanced the iNOS expression in 
astrocytes (Ding et al, 1997). However, Pahan et al (1998) reported that treatment 
with TNF-a alone could not trigger iNOS expression. The difference maybe due to 
the methods used, in which Northern blot analysis they used is less sensitive enough 
in detecting small mRNA changes. Further studies found that the iNOS induction was 
primarily regulated by TNF-R2 (Figs. 63 & 64)，the subtype mediating astrocyte 
proliferation (Figs. 3 & 4). This suggests that iNOS maybe involved in the 
TNF-a-induced proliferation. This deduction is supported by studies that NO has 
proliferative activity (Magnusson et al.，1996). However, the role played by iNOS in 
astrogliosis remains to be described. Both PKA and PKC inhibitors suppressed the 
TNF-a induced iNOS expression (Figs. 65 & 66). We speculated that the 
PMA-insensitive atypical PKC maybe involved, as PMA could not trigger iNOS gene 
expression. 
Besides, it was observed that isoproterenol induced iNOS gene expression, 
while propranolol reduced the TNF-a-induced iNOS mRNA level (Fig. 69). The 
induction was likely not mediated via cAMP, as dbcAMP did not induce the iNOS 
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expression (Fig. 70). Although Pahan's group (1997) found that cAMP attenuated 
iNOS expression in primary astrocytes, we did not observe any significant reduction 
caused by dbcAMP applied to the cells (Fig. 70). The difference maybe because these 
authors used serum-free medium for cell culture. Further studies showed that 
(32-antagonist strongly enhanced the TNF-a-induced iNOS expression, but that 
reverse observation was seen with (31-antagonist (Fig. 72). This suggests that an 
unidentified mechanism maybe used by p-ARs to modulate iNOS gene. Altogether, 
the TNF-a-induced iNOS expression is mediated via or controlled by P-adrenergic 
mechanism in cultured rat astrocytes. 
4.5. Possible source of P-agonists 
In the present study, we found that TNF-a could induce pi- and Pi-AR 
expressions and that both receptor subtypes played a regulatory role in TNF-a, 
TNF-R2 and iNOS expression. One of the interesting points worthy of discussion is 
the source(s) of the p-agonist in our study. Since serum was one of the ingredients 
added in our cultures, and that adrenaline and noradrenaline are known to be present 
in the serum (Dibner and Insel, 1981), it is likely that serum is the possible source of 
P-agonist. Moreover, Wu et al (1985) found that astrocytes responded to isoproterenol 
differently in serum-supplemented and serum-free medium. Therefore, further 
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experiments should be done to see whether the effect of TNF-a is serum-dependent. 
4.6. Conclusions 
Astrogliosis is characterized by the proliferation, GFAP overexpression and 
morphology changes of astrocytes. Pro-inflammatory cytokines, particularly TNF-a, 
has been considered as the major factor of astrogliosis as it was found in scars of MS 
patients. Our present study found that TNF-a stimulates the proliferation of cultured 
astrocytes and its proliferative action is transduced through TNF-R2. This cytokine 
can enhance the proliferation by upregulating the endogenous TNF-a and TNF-R2 
levels. TNF-a enhances astrogliosis by inducing GFAP overexpression in astrocytes 
(Zhang et al, 2000). Besides, it can induce astrogliosis indirectly by elevating the 
p-AR densities, since P-AR activation can cause astrogliosis (Hodges-Savola et al., 
1996). Thus, attenuating the TNF-a action and/or production may control and slow 
down the astrogliosis. 
Our signal transductions studies showed that TNF-R2 transduces the TNF-a 
‘ signals to increase the expressions of endogenous TNF-a, TNF-R2 and P-AR genes. 
Therefore, selective blocking the TNF-R2 can reduce the levels of these genes and in 
turn lessen the severity of astrogliosis. Besides, PKC is required for the induction of 
these genes by TNF-a. So, astrogliosis can also be reduced if the PKC signaling 
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pathway is blocked or controlled. However, the PKC isoforms involved should be 
determined in order to increase the specificity of treatments. Furthermore, 
transcription factors are activated by TNF-a; however, the exact role played by them 
in astrocytes remains to be elucidated. 
The involvement of p-adrenergic mechanism in astrogliosis has recently been 
discussed (Hodges-Savola et al.’ 1996; Sutin and Griffith, 1993). Our study found that 
P-adrenergic mechanism does not stimulate astrocyte proliferation. Therefore, it 
seems to promote astrogliosis through other mechanisms, such as GFAP induction 
(Tsang, unpublished observation). Although p-adrenergic mechanism is not involved 
in the TNF-a-triggered astrocyte proliferation, (3-antagonists enhances the 
TNF-a-induced TNF-a and TNF-R2 expressions, but p-AR activation reduces that of 
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